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Brought into humans through zoonotic transmission (1, 2) HIV-1 and -2, the causative agent of the 
acquired immunodeficiency syndrome (AIDS) have quickly generated one of the most serious global 
epidemics. Easily transmitted through sexual contact, by blood/blood products or vertically from 
mother-to-child, more than 34 million deaths worldwide since its discovery in the early eighties (3-5) 
and 2.5 million new infections per year can be attributed to HIV-1. Thereby, HIV-1 is not only an issue 
of the developing countries in which prevalence reaches up to 25% (Botswana, Sub-Saharan Africa, 
WHO Report, 2012) but also for the industrialised nations where similarly millions are infected (Fig. 
1). The ultimate consequences of HIV-1 infection such as reduced life expectancy, vulnerability to 
opportunistic infections and the development of cancers represent an immense burden to the patient and 
do impact the performance of health systems and working capacity in severely affected areas. The fight 
against HIV and its further spread has thus become a major goal of worldwide efforts. Since attempts to 
develop a preventive vaccine failed till now, research has refocused in the last years on unravelling 
HIV’s biology and studying natural infection to decipher new therapeutic intervention strategies and to 
improve existing antiretroviral therapy (ART). Remarkable progress has been made in these areas as  
 
 
Fig. 1 Geographical distribution of HIV-1 infections worldwide. The numbers of adults and children infected with HIV-1 in 2011 are given in 
dark blue and represent an average of reported HIV-1 infection from different sources (numbers in brackets). Figure adopted from the 





well as in establishing infrastructures for collaboration of scientists around the world to accelerate the 
transfer of scientific advancements from bench to bedside. Driven forward and coordinated by 
organisations like WHO, UNAIDS and IAVI and accompanied by a profound financial support ($2.64 
milliards in 2011, Treatment Action Group Report, 2013) the joint efforts and particularly the extensive 
use of ART have reduced the level of worldwide infections by 20% when compared to 2001 and have 
minimised AIDS-related deaths from 2.5 million people in 2005 to 1.7 million in 2012 (UNAIDS Global 
AIDS Report, 2012). However, problems associated with further scale-up of ART such as drug supply, 
costs, the development of resistance, side effects and the fact that ART cannot cure or prevent HIV 
infection demonstrate that it is not the magic bullet in the fight against the infection and associated 
diseases. In contrast, a safe and efficient vaccine able to eradicate HIV-1 would be a major step forward 
and is therefore urgently needed. The following sections shortly review the current knowledge on HIV 
biology and vaccine development and provide background information on the strategy to be investigated 
in this thesis. 
 
1.1 Molecular organisation of HIV-1 and virus replication 
In the family of the Retroviridae, HIV-1 together with HIV-2, the simian, bovine and the feline 
immunodeficiency viruses belong to the genus of the lentiviruses which are all characterised by 
persistent infection with a slow progressing course of disease. Driven by the flanking long terminal 
repeats (LTRs), the HIV proviral DNA of about 9.5 kb encodes the typical Gag, Pol and Env proteins 
essential for virion assembly and replication (Fig 2). Furthermore, the transcription of additional 
auxiliary proteins including Vif, Vpr, Vpu, Ref, Tat and Nef, which are involved in regulatory functions 
and immune evasion (6, 7) renders HIV a complex retrovirus (Fig. 2). The Gag protein-derived cleavage 
products, namely Matrix (MA), Capsid (CA) and Nucleocapsid (NC) build up the virion in which two 
copies of unspliced, positive ssRNA genomes were packaged into the centre of a spherical CA core (Fig 
2). This core domain also contains the cleavage products of Pol encompassing the Protease (PR), 
Integrase  (IN) and Reverse transcriptase (RT) enzymes essential for virus maturation and the early steps 








Fig. 2 HIV-1 virus structure and molecular organisation. Upper panel: the individual components of an HIV-1 particle, accessory proteins and 
enzymes are indicated and labelled on the right. Gp160, gp120 and gp41 correspond to the full-length Env, SU and TM proteins as mentioned 
in the text. Note that usually only about 15-20 viral spikes can be found on the virion surface. Lower panel: the localisation of HIV-1 encoded 
proteins within the HIV-1 genome. Figure taken from (9). 
 
harbours around 15 viral spikes consisting of trimers of Env, the 160 kDa glycoprotein which is 
eventually cleaved into the gp120 surface protein (SU) and the gp41 transmembrane envelope (TM) 
protein. These components assemble at the plasma membrane and bud as immature, non-infectious 
particles with 80-120 nm in diameter and finally gain infectivity after Gag precursor processing through 
the viral PR. For infection, mature HIV-1 virions first encounter cells by non-specific attachment to 
charged groups on the cell surface such as heparin sulphate proteoglycans (lectins, e.g. DC-SIGN). 
Although virus entry can be mediated through endocytosis (10), the main route of infection uses 
sequential binding of the Env SU subunit to the CD4 receptor and CCR-5 or CXCR-4 chemokine co-
receptors which are presented on T-helper lymphocytes, monocyte-macrophages, follicular dendritic 
cells, Langerhans cells in the skin and microglia in the nervous system (11, 12). Additional target cells 
(NK cells, epithelial cells) might be entered by using alternative co-receptors or the galactosyl ceramide 
receptor binding domain located in gp41 (13, 14). The binding of SU to the cellular receptors exposes 
the TM protein which in turn is able to insert its N-terminal, hydrophobic fusion peptide (FP) into the 
target cell membrane to adopt a pre-hairpin conformation. Subsequently, conformational changes 
leading to the assembly of the N- and C-terminal helical regions (NHR, CHR) to a coiled-coil (six-helix 
bundle) brings the viral and the cellular membrane into close proximity and induces lipid mixing and 






Fig. 3 Model of the Env mediated fusion reaction. (I) Before attachment, the membrane anchored native envelope trimer comprising the 
SU subunit (blue) and the TM protein with its condensed N- and C-terminal helical regions (NHR, CHR in light and dark red, respectively) is 
presented on the virion surface. Attachment of the SU protein to CD4 (II) and co-receptor engagement (III) triggers conformational changes 
in SU that allows the hydrophobic fusion peptide (yellow helices) to insert into the cellular target membrane. Association of NHR and CHR 
domains to a six-helix bundle eventually leads to approximation of both lipid membranes and cell fusion. Figure from (15). 
 
 
into the cytoplasm of the infected cell, where a DNA copy of the virus genome is produced by the RT. 
The linear DNA associated with additional proteins forms the pre-integration complex which is then 
actively transported into the nucleus for integration into the cellular genome with the help of the IN. 
Upon transcription of the proviral DNA, another cycle of replication begins (Fig. 4).  
 
 
Fig. 4 The replication cycle of HIV-1. After attachment of virus particles (red, left) to CD4 and co-receptors, virus and cellular membranes 
fuse and the virion content is released into the cytoplasm where cDNA synthesis is accomplished by the Reverse transcriptase (RT). Associated 
with Integrase (IN), Matrix protein (MA) and the Viral protein R (VPR) the pre-integration complex translocates through the microtubule 
network into the nucleus where viral DNA is integrated into the genome by IN. Expression of viral genes is achieved through binding of the 
HIV-1 transactivator (Tat) and transcription by cellular polymerase (RNAPII). Viral structural and accessory proteins along with two copies of 





1.2 Natural HIV-1 infection and immune responses 
After transmission of the virus into a new host, initial infection in the genital mucosa or the gut 
associated lymphoid tissues (GALT) is established by a small number or even a single founder virus 
which is best adopted to the new environment (17, 18). The presence of infected cells, predominantly 
intraepithelial α4β7+/CCR5+/CD4+ resting T-cells (19, 20) together with mucosal chemokines attract 
plasmacytoid DCs to the site of infection which trigger the influx of additional permissive CD4+ T cells 
by expressing an array of inflammatory cytokines (21). Within few days, the complex interplay of innate 
and adaptive immunity along with the error-prone reverse transcription of HIV genomes lead to the 
rapid formation of viral quasi-species in the eclipse phase, which eventually allows the dissemination 
of virus throughout the GALT and into the draining lymph nodes (Fig 5). The following acute phase is 
characterised by an explosive virus expansion, evident by the presence of viral RNA in the blood with 
levels that can reach 106-107 copies/ml, which allows viral reservoirs to be established. The initial 
infection is confined by the onset of a more generalised immune response comprising innate and early 
adaptive immune responses (see below). As an result, a balance between virus turnover and immune  
 
 
Fig. 5 CD4 T-cell numbers and viral load during different stages of HIV infection. After primary infection a decline of CD4 T cells and drastic 
increase of plasma viral loads characterise the acute phase (3-7 weeks after infection) in which viral reservoirs are established. Virus spread 
is condemned by innate immunity and first CTL responses that stabilise at the viral set-point in which clinical latency establishes. Within 
years, when CD4 cells decline below an individual threshold (~400 cells/µl) the body is incapable to further control virus replication and a 
rebound of plasma viral RNA becomes obvious. At this stage, the body is highly susceptible to opportunistic infections and other diseases 




responses leads to a preliminary stabilisation of virus spread and  plasma viral loads at the viral set-point 
and introduces a chronic phase with clinical latency. This asymptomatic phase can last from months to 
decades, dependent on the genetic background of the individual (23) and viral loads at set-point (24). 
Throughout this period, a continuous loss of CD4+ T cells is a hallmark of progressive HIV infection 
(Fig. 5). This has been proposed to be caused by various means (reviewed in (25)), including direct 
killing of infected cells by HIV-specific CD8+ T cells or antibodies, apoptosis of bystander cells through 
HIV-1 accessory proteins and abortive infection (26), chronic activation of the immune system resulting 
in increased T cell turnover as well as the destruction of lymphoid tissues mandatory for restoration of 
T cell numbers. At the final stages, when CD4+ T cell numbers are very low, the immune system is 
unable to further control the virus and a rebound of antigenemia and viral loads is observed (Fig. 5). The 
weakened immune system gets susceptible to diseases and opportunistic infections like pneumonia, 
dementia, wasting and others, eventually leading to the death of the patient. Notably, this is despite an 
intensive effort of the immune system to clear the virus (Fig. 6).  
 
 
Fig. 6 Immune responses during natural HIV-1 infection. After virus transmission first responses are mediated by innate immunity including 
acute phase proteins like serum amyloid A and the virus inhibitory peptide VIRIP. Virus dissemination is paralleled by pro-inflammatory and 
antiviral cytokines within the first three weeks of infection. Subsequently, seroconversion becomes evident by antibodies against structural 
proteins including Gag and Env. With onset of cellular immunity, first CD8+ cytotoxic T-cells viral loads stabilise at the set-point before viral 
quasi species arise. First neutralising antibody responses to the founder virus can be detected ~80 days after infection, antibodies with a 






First responses are mediated by innate immunity comprising NK and dendritic cells, cellular restriction 
factors like APOBECs, Trim5α, SAMHD1 and antiviral cytokines such as type I interferons, IL-15 and 
IL-18 (27). Although these mechanisms are able to constrain viral replication to a certain degree, they 
lead to an influx of susceptible CD4+ T cells to the foci of infection which serve as new target cells for 
virus spread. Control of peak viraemia sets in with the raise of CD8+ T cell responses which are directed 
against Env and Nef in early phases (8-10 days after infection) and to more conserved epitopes in Gag 
and Pol after 1-2 weeks (28). Humoral responses to HIV directed to the Env protein are limited to low-
affinity, non-neutralising antibodies of the IgM and IgG subtype during acute infection (29). Whereas 
such antibodies were found to be involved in immune complex formation and to support antibody-
dependent cellular cytotoxicity (ADCC), they are ineffective in supressing viral loads (29-31). The first 
neutralising antibodies (nAb) develop after ~80 days of infection (Fig. 6). However, their efficacy is 
mainly restricted to highly immunogenic, non-conserved regions of autologous/founder virus, from 
which HIV can readily escape without remarkable loss of viral fitness. Antibodies with a broadly 
neutralising phenotype (bnAb) develop in about 20 to 30% of infected individuals and are in some cases 
able to neutralise up to 95% of all circulating HIV strains (32, 33). Their induction has been found to 
correlate with high viral loads, low CD4+ T cell counts and with the time (2-4 years) the individual is 
infected (34-36). Taken together, these studies on natural infections demonstrate that the body is 
principally capable to control virus replication through effective CTL and antibody responses. 
Triggering such immune responses in healthy individuals should therefore provide a way to control or 
prevent subsequent HIV infection. The next section briefly summarises attempts to translate these 
findings for HIV vaccine development. 
 
1.3 HIV vaccine development 
Since the first appearance of AIDS in the eighties, the development of a safe and effective HIV-1 vaccine 
was considered to be essential to avoid further spread of the disease. However, the initial enthusiasm 
was quickly dampened by the finding that traditional vaccine approaches like live attenuated viruses 
although providing protection (37, 38), are impractical due to reasonable safety concerns (39, 40). 




immunogenic, provide protection only against closely related viruses and inactivation procedures may 
represent a risk-factor or denature antigens in a way that makes them incapable to mount efficient 
immune responses (41, 42). Since then, further studies have been conducted on various forms of 
immunogens such as live or non-replicating recombinant vectors expressing HIV antigens, DNA 
vaccines, subunit vaccines including virus like particles, recombinant Env and gp41 proteins, epitope 
scaffolds, HIV synthetic peptides, artificial mosaic antigens and combinations thereof (reviewed in (9)). 
By inducing various degrees of immune responses and protection, several of them have proceeded to 
Phase I and II clinical trials and four have been tested in large cohorts of healthy volunteers (43). With 
exception of the most recent RV144 trial in Thailand (16.400 participants, 31% vaccine efficiency (44)), 
none of the strategies have proven to be able to induce protective immunity, some even enhanced 
infection rates (45-48). Historically, these vaccine approaches were designed to induce either bnAb or 
to trigger cellular immunity to control virus replication and decelerate disease progression. As both 
approaches failed so far when applied alone, it is assumed that an effective vaccine will probably have 
to stimulate both arms of immunity. However, considering the fact that control of virus replication is 
unnecessary in presence of a profound bnAb response that prevents infection of any cells and HIV 
genome integration, triggering humoral immune responses could provide benefits compared to a T cell-
based vaccine approach as will be highlighted below. 
 
1.4 The envelope proteins of HIV-1 as vaccine antigen for induction of bnAb 
The envelope proteins represent the major target of nAb during HIV-1 infection and several bnAb have 
been isolated from naturally infected individuals (Figure 7, Table 1). By binding to their epitopes, they 
mask domains within Env that are essential for receptor or co-receptor engagement or inhibit fusion of 
virions with the target cells. In addition, most of the bnAb can also block virus transmission at the 
virological synapse or show indirect antiviral activities by permitting killing of infected cells through 
mechanisms of ADCC and ADCVI and are thus also effective against intracellular HIV-1 (30, 49-52). 
In the SU subunit, immunogenic regions comprise the CD4 binding site and CD4 receptor binding-
induced (CD4i) epitopes as well as variable loops (V2, V3, V4) with varying degrees of glycan 






Fig. 7 The HIV-1 envelope spike and its recognition by neutralising antibodies. Names of target sites and their respective localisation within 
Env are indicated in colour. Antibodies binding to the corresponding regions (black) are listed below. Note that additional sites known to be 
target of neutralising antibodies and mentioned in the text (e.g NHR, V3 loop antibodies) are not illustrated here. Figure adopted from (53) 
 
external region (MPER) located in close proximity to the transmembrane domain, but nAb targeting the 
NHR domain have also been described (54, 55). Convincing evidence that such antibodies can prevent 
HIV-1 acquisition and provide sterilising immunity comes from passive immunisation studies (56-60) 
and gene therapy approaches inducing the production of bnAb in the transgene host (61, 62). The need 
for high plasma antibody levels in these reports has been criticised as they would be hard to achieve by 
an immunisation regimen. Recent data demonstrated, however, that even low levels of bnAb are 
sufficient to provide protection if antibodies are selected that show excellent breadth and potency (63). 
The obstacles in using Env or subunits thereof as vaccine antigen lie in in their inability to induce high-
titre neutralising antibody responses with sufficient breadth (64-66). Most of the HIV-1 bnAb described 
to date show unique properties such as a high degree of somatic mutation, use of prolonged CDRH3 
loops for epitope recognition, need for lipid for efficient binding and self-reactivity, triggering their 
depletion during B- cell selection (67). Together with their delayed development during natural infection 
(2-4 years) and the need for high viral loads during the acute phase, this points to a role of increased 
antigen exposure and affinity maturation as a requirement for the induction of these kind of antibodies. 





 Table 1. Selected broadly neutralising antibodies and their epitopes within HIV-1 Env 




2G12 gp120 Glycans Yes (68) 
b12 gp120 CD4bs No (69) 
VRC01 gp120 CD4bs No (70) 
PG9/PG16 gp120 V2/V3 loop Yes (71) 
PGT121/128 gp120 V3 loop Yes (72) 
D5 gp41 NHR No (54) 
HK20 gp41 NHR No (55) 
2F5 gp41 MPER No (73) 
4E10 gp41 MPER No (74) 
Z13e1 gp41 MPER No (75) 
10E8 gp41 MPER No (76) 
     
 
allow sustained antigen delivery and immune stimulation (see next section). As HIV-1 epitope, the gp41 
MPER domain was selected as it shows a higher degree of conservation and is continuous compared to 
the variable and more complex, discontinuous and often glycan-dependent epitopes within gp120 (77). 
Notably, bnAb targeting this domain such as 2F5, 10E8 and 4E10 are characterised by a high degree of 
somatic mutation and prolonged CDRH3 loops and thus might require extended periods of antibody 
maturation (67, 77). Despite its lower complexity, the MPER is yet a challenging vaccine target and 
most attempts to induce MPER-specific bnAb also failed (reviewed in (78)). The structural flexibility 
of these residues which is mandatory to promote fusion and the lack of knowledge which of these MPER 
conformations induces the desired antibodies is the major problem for MPER antigen design approaches. 
Furthermore, although there is evidence for the need of lipids to enhance antibody binding, its 
requirement for the induction of nAb is largely unknown. Under physiological conditions, the MPER 
adopts an α-helical structure (79-81) which is altered upon antibody recognition (82-85). In case of 2F5, 
binding induces an extended β-turn structure in the 664DKW666 core residues (82, 84, 85) whereas 4E10 
binding stabilises the α-helical character of its epitope (86). In line with this, constraining the MPER 
into β-turn or α-helical conformations through chemical modifications or suitable epitope scaffolds 
enhances 2F5 and 4E10 binding, respectively (5, 87-91). Recent investigations supported an interaction 
of the MPER with the N-terminal fusion peptide proximal region (FPPR, Fig. 8) of gp41 and also 
showed that peptides corresponding to this domain increased binding of 2F5 to its epitope (92-96). This 
was attributed to a FPPR-induced orientation of MPER residues coinciding with an increased level of 




terminal residues (84, 92, 95). As this structure resembles the conformation reported for the MPER in 
an antibody bound form, it might represent the initial B-cell trigger for induction of 2F5-like antibodies. 
As a consequence, some antigens used in this study also included the FPPR domain in order to test if its 
reported constraining properties can translate into an improved antibody response during immunisation. 
 
Fig. 8 Schematic presentation of gp41 of HIV-1. (A) Characteristic subdomains are indicated. FP – fusion peptide, FPPR – fusion peptide 
proximal region, E1- FPPR derived domain, NHR/CHR – N-terminal and C-terminal helical regions, MPER, membrane proximal external region, 
E2 –MPER derived domain, MSD – membrane spanning domain, C-C – cysteine loop, TM – transmembrane envelope protein. The epitopes 
of the broadly neutralising antibodies 2F5 (ELDKWAS) and 4E10 (WFNITNWLW) within the MPER/E2 domain are underlined (B) Model of 
gp41 in an very early or post-fusional state in which NHR and CHR domains are in close proximity. Note that only one molecule of the actually 
trimeric complex is shown. 
 
 
1.5 Foamy viruses 
In the group of retroviruses, the spuma- or foamy viruses (FV) constitute the only members of the 
Spumaviriniae sub-family which comprises FVs from various species including primates, non-human 
primates, cats, cattle, horses and sheep (97). Initially described in the early 50’s and later isolated from 
a human nasopharyngal carcinoma cell line they were named according to the foamy-like appearance of 
infected cells in culture (98-100). Remarkably, the strong cytopathic effect of FVs observed in vitro is 
in stark contrast to their behaviour in naturally or experimentally infected hosts. Here, no clear 
association to any pathology or disease could be addressed so far, which is assumed to be an result of at 
least 30 million years of virus/host co-evolution (101-103). FV were set apart from the orthoretroviruses 
due to several unique characteristics in their virus biology and replication strategy (104). As all 
retroviruses they encode the canonical gag, pol and env genes as well as at least two accessory bel genes 
(between env and LTR) giving raise to the Bel-1/Tas (transactivator of spumaviruses) and Bet proteins 
(Fig. 9). However, differences comprise the translation of Pol from a spliced mRNA transcript instead 
of synthesis and cleavage of a Gag-Pol fusion protein (105, 106), incomplete cleavage of Pol proteins 




env (108-110). Similar to the Hepadnaviruses, reverse transcription of FV RNA occurs late during 
replication resulting in DNA-containing viral particles (111-113). Furthermore, FV particle egress is 
dependent on the presence and interaction with the FV envelope protein as Gag does not contain a 
membrane targeting signal (114, 115). Notably, this specific Gag/Env interaction currently prevents the 
use of heterologous envelopes for pseudotyping FV (116). Whereas FV basic research has been 
conducted for more than two decades now, attempts to exploit their potential for clinical applications 
has just recently advanced into practice (117-119). FV show several properties that makes them 
interesting vectors for gene therapy and vaccine purposes as will be outlined in the next section. 
 
 
Fig. 9 Molecular organisation of foamy viruses and the infectious FFV clone pCF-7 used in this study. In the infectious FFV clone pCF-7 
(bottom), the U5 region of the 5’ LTR is replaced by the strong CMV-immediate early  promoter (CMV-IE) to trigger high level virus production 
upon transfection and avoid LTR recombination events during propagation in E. coli.  
 
1.6 Replicating foamy viruses as vaccine vectors 
The absence of any obvious disease upon natural or experimental FV infection is probably one of the 
most attractive properties of these viruses for vaccine and gene therapy applications. Therewith, FV 
vectors show a similar or higher safety profile compared to currently used replication-competent systems 
(Table 2) that are usually used in highly attenuated forms on the cost of immunogenicity (adenoviruses, 
measles virus, Sendai virus), have the potential to induce neurotoxicity (vesicular stomatitis virus) or in 
case of CMV are incompatible for use in pregnant woman, young children and immunocompromised 
patients (120). Next to such safety concerns, a major drawback of established systems like measles and 
polio is their extensive use within the human population in the past as well as their high natural 
prevalence in man in case of herpes and adenoviruses. To avoid issues of vector directed pre-existing 





Table 2. Selected replicating vectors currently used for HIV vaccine development. Modified from (120)  
Replication-competent vector Stage of development Reference 
DNA Viruses   
Human Adenovirus type 4 Preclinical/clinical (121) 
Human Adenovirus type 5 NHP (122, 123) 
Human Cytomegalovirus Preclinical/clinical L. Picker Group 
Herpes Simplex Virus NHP (124) 
Vaccinia Virus - Tiantan Clinical Trial (125) 
Vaccinia virus – NYVAC-KC NHP (126, 127) 
RNA Viruses (negative strand)   
Canine Distemper Virus NHP (128) 
Influenza Virus NHP (129) 
Measles Virus Clinical Trial (130-132) 
Sendai Virus Clinical Trail (133, 134) 
Vesicular Stomatitis Virus Clinical Trail (135-138) 
RNA Viruses (positive strand)   
Poliovirus NHP (139, 140) 
Semliki Forest Virus chimeras NHP (141, 142) 
Yellow fever virus NHP (143, 144) 
 NHP- Non human primate studies 
 
non-human origin provide certain benefits (145). In this work efforts were focused on the development 
of a feline FV (FFV) vector, as this system provides a versatile way to analyse new chimeric vectors in 
an authentic and fully immunocompetent small animal system for preclinical testing (146). However, 
for future application in humans additional advantages become noteworthy (Table 3). As mentioned 
above, the first FV isolate was obtained from a human patient. In fact, humans do not represent a natural 
host of FV and the human isolate (HFV) was later found to be zoonotically transmitted from chimpanzee 
and thus renamed to SFVcpz(hu) or PFV (147, 148). Further studies performed to detect FV have 
demonstrated a low (~2 %) prevalence of primate FV in humans which is limited to certain subgroups 
with direct contact to infected simians like meat hunters and animal care takers (103, 149-151). 
Monitoring FV infection in these individuals for more than 20 years suggests that humans represent 
dead-end hosts with no further spread of virus to relatives or spouses (150, 152-155). Despite its 
apathogenic character, FV infection is persistent and induces strong humoral and cellular immune 






 Table 3. Properties of FV vectors beneficial for gene therapy and vaccine purposes 
Property/Advantage Reference 
 Persistent infection with no associated pathogenicity (118, 149, 156-158) 
 Infection induces strong humoral and cellular immune responses (118, 159-161) 
 Preferential integration sites and non-integrating vectors available (162-166) 
 Low prevalence in humans avoids issues of pre-existing immunity (149, 151, 154, 167) 
 Genetic stability and high packaging capacity (103, 168, 169) 
 Active replication in mucosal and lymphoid tissues (170-173) 
  
 
immune stimulation. As they mainly replicate in mucosal and lymphoid tissues, they are furthermore 
also suitable for induction of immune responses directly at the main site of HIV entry (170-173). Still, 
as all retroviruses FV integrate into the genome of the host cell raising the possibility for insertional 
mutagenesis or proto-oncogene activation (174). By comparing different vector systems used for gene 
therapy, it has been found that FV show preferential integration into non-active regions of the genome 
which reduces the risk for such adverse side effects (162, 165, 166). In line with this, no evidence for 
clonal expansion of transduced cells was observed after four years of follow-up of dogs treated gene-
therapeutically with a FV expressing the canine leukocyte adhesion factor CD18 (117, 175). 
Alternatively, non-integrating FV vectors that are maintained through episomal replication have also 
been developed (163). Taken together, these facts encourage the further exploration of these viruses for 
treating disease including their usability as HIV vaccine vectors. 
 
1.7 The foamy viral envelope protein as HIV-1 vaccine epitope scaffold 
FV Env is translated from a single-spliced mRNA encoding the gp130 precursor protein and targeted 
by its N-terminal signal peptide (envelope leader peptide, ELP) to the endoplasmic reticulum for 
cleavage by furin-like proteases into a SU (gp80) and TM (gp48) subunit (176). Upon its way through 
the trans-Golgi network it gets further modified by N-linked glycosylation at 14 out of 15 possible sites 
in case of PFV (177). Due to a specific interaction of FV ELP with Gag essential for budding and the 
presence of the internal promoter within Env driving expression of accessory genes, simple replacement 
of FV Env through heterologous Envs such as HIV gp160 is not feasible (108, 115, 178-180). As a first 





Fig. 10 Comparative secondary structure analysis of the HIV-1 and FV TM proteins. Secondary structure predictions of gp41 of HIV-1-HXB2 
or gp48 of the FFV-FUV isolate were made using the program PROOF and the probabilities of individual residues to form α-helices (red), β-
sheets (blue) and loops (green) are depicted. Both proteins show the characteristic TM sub-domains comprising the fusion peptide (FP), N- 
and C-terminal α-helical regions, a β-sheet and loop rich central element stabilised by cysteines (C) and the membrane spanning domain 
(MSD) anchoring the protein in the viral membrane. Note that the subsequent cytoplasmic tail is shortened in case of HIV-1 gp41. The 
membrane proximal external region (MPER) of gp41 which is targeted by several bnAb is also indicated. 
 
 
useful for several reasons. First, among the retroviruses the overall structural elements encoded in the 
TM subunit are highly conserved as an result of their similar function in membrane fusion. This holds 
true for the larger FV TM proteins (Fig. 10), which show similar structural organisation with a 
hydrophobic fusion peptide, N- and C-terminal α-helical regions connected by an extended β-sheet, loop 
and cysteine-rich segment, a membrane spanning domain for anchorage in the viral membrane as well 
as a cytoplasmic tail (181). In previous immunisations studies using various gammaretroviral TM 
proteins including the porcine endogenous retrovirus (PERV), feline leukaemia virus (FeLV) and Koala 
retrovirus (KoRV), neutralising antibodies were easily induced and immunogenic regions identified in 
the FPPR and MPER of these proteins (182-186). Moreover, a partial sequence homology within the 
MPER epitopes of these viruses and the phylogenetically distant HIV MPER domain was evident (187). 
These data suggested that the MPER is a conserved target of antibodies during retroviral infection and 
thus, epitopes targeted by nAb might be also expected to be located in the FV TM protein. Second, as 
an influence of lipid components on HIV-1 MPER epitope accessibility and structure has been 




essential for the induction of antibodies with similar properties including neutralisation. Third, the 
envelope proteins of FVs have been shown to trimerise as the parental Env proteins of HIV-1 (191). 
Hence, presentation of chimeric Envs in a similar trimeric context could also be anticipated. Fourth, the 
FV envelope protein is presented on the virion surface in stable hexameric rings at a unusual high density 
(180), resulting in an abundant presentation of the intended vaccine epitope. Finally, the PFV envelope 
proteins have been found to bud in the absence of Gag in the form of subviral particles (192-194). As 
HIV-1 epitopes would be presented here on the particle surface and in a lipid environment as well, such 
antigens constituted an interesting alternative vaccination platform in case that epitope insertion into the 
FV backbone is incompatible with virus replication.  
 
1.8 The foamy viral Bet protein as carrier for HIV-1 epitopes 
In a second strategy aiming to induce HIV-1 neutralising antibodies, the Bet protein of FFV was 
employed as carrier protein. FFV Bet is a 43 kDa, cysteine-rich accessory protein encoded downstream 
of env (Fig. 9) and arises from an splicing event fusing N-terminal residues of Bel-1 to the complete 
Bel-2 open reading frame (195). Bet function has been linked to resistance to superinfection (196), viral 
latency (197) and plays a key role in counteracting the cellular restriction factor APOBEC3G (198-200). 
Several reasons rationalised the use of Bet as fusion partner for HIV epitopes. The Bet protein is highly 
expressed in FV infected cells (159) and a strong target of antibodies during natural and experimental 
FV infection (161, 201, 202). Furthermore, Bet has been described to be secreted as Bet or Env-Bet 
fusion protein and to be taken up by neighbouring cells (203-205). Epitopes fused to Bet should therefore 
benefit from its immunogenicity, will be distributed to neighbouring cells and when secreted, allow the 
stimulation of surveying immune cells with proteasome-unprocessed conformational epitopes. Although 
this strategy does not support the presentation of HIV-1 epitopes on the virus surface or their placement 
in a lipid environment as in case of the FFV TM-based approach, the modification of Bet as an accessory 
protein is less invasive than changing a structural protein such as Env and thus was more likely to result 






1.9 Aim of this thesis and work flow 
The induction of bnAb against HIV-1 by classical immunisation regimens remains an elusive goal. The 
recent findings that during natural HIV-1 infection such antibodies arise only after years, their induction 
correlates with high viral loads and the fact that most of the described bnAb show an unusual high degree 
of somatic mutation supported the view that prolonged antigen exposure and affinity maturation might 
play essential roles during their development. To investigate this, the objective of this thesis was to 
establish a novel vaccine epitope delivery platform based on apathogenic, replicating FV that should 
allow extended antigen delivery and maturation of immune responses to conserved epitopes targeted by 
HIV-1 bnAb. As later testing of such new chimeric viruses in a small animal system was envisaged, 
emphasis should be laid on the feline FV model vector to allow a pre-clinical evaluation in cats before 
transfer to primate FV. Two scaffolding strategies were investigated to deliver the conserved HIV gp41 
MPER domain as a well characterised target of several bnAb including 2F5, 4E10 and 10E8. In the first 
approach comprising the FFV TM protein, the immunological properties of FFV TM were examined by 
studying the immune response to this antigen in naturally infected cats and TM protein immunised 
animals. Epitopes identified by this means were used to design FFV/HIV-1 Env hybrid antigens and the 
compatibility of epitope exchange with envelope function and virus replication was analysed. In the 
second approach, fusion proteins of Bet with the HIV-1 MPER as well as FPPR-MPER antigens were 
generated and characterised by biochemical and immunological means to explore the potential of the 
Bet protein as epitope carrier. In parallel, a set of novel HIV-1 FPPR-MPER antigens was designed with 
the intention to improve MPER epitope presentation and antigenicity. In a next step, compatibility of 
subcloning of suitable Bet/HIV-inserts to infectious FFV and the replicative potential of these vectors 








Fig. 11 Schematical overview of the strategies for HIV epitope delivery by FV vectors used in this study. The three independent projects are 




2. Material and methods 
2.1 Materials  
2.1.1 Antibiotics 
Name Working concentration Vendor 
Ampicillin 100 µg/ml Roth 
Chloramphenicol 34 µg/ml Roth 
Penicillin/Streptomycin 100 U/ml, 100 µg/ml PAA 
Kanamycin 25 µg/ml Fluka 
Gentamycin/G418 10 µg/ml Biochrom 
 
 
2.1.2 Antibodies and antisera 
Primary Antibodies/ Serum Vendor/Source Dilution 
Mouse Anti-RGS-His Qiagen, Germany 1:3000 
Mouse Anti-Penta-His Qiagen, Germany 1:3000 
Goat Anti-GST GE Healthcare, Germany 1:5000 
Mouse Anti-β-Actin Sigma-Aldrich 1:5000 
2F5 Polymun Scientific, Austria 0.2-50 µg/ml 
4E10 Polymun Scientific, Austria 0.2-50 µg/ml 
Goat Anti-FFV-TM Mühle et al., 2011 1:2000 
Rat Anti-Bet Mühle et al., 2013 1:3000 
Rat Anti-HIV-E1 Jürgen Kreuzberger, RKI 1:2000 
Normal Goat Serum Sigma-Aldrich 3-10% 
Secondary antibodies Vendor/Source Dilution 
Rabbit Anti-Rat, Anti-Goat, Anti-
Human, Anti-Mouse-IgG-HRP 
Dako 1:3000 
Goat Anti-Hamster-IgG-HRP LifeSpan Biosciences 1:2000 
Goat Anti-Cat-IgG-Fc-HRP Bethyl Laboratories 1:3000 
Goat Anti-Rat, Anti-Mouse, Anti-
Cat, Anti-Hamster-IgG DyLight649 
Jackson ImmunoResearch 1:500 
Rabbit Anti-Goat-IgG DyLight649 Jackson ImmunoResearch 1:500 
Goat Anti-Rat-IgG-FITC SantaCruz Biotechnology 1:500 








Standard buffers and stock solutions 
 
PBS 137 mM NaCl,  2.7 mM KCl, 10 mM Na2HPO4,  
1.8 mM KH2PO4, pH 7.2 
PBS-T    PBS, 0.05% Tween 20 
TBS    50 mM Tris.HCl, 125 mM NaCl, pH 7.5 
Proteinase K solution  1 ml 10x PCR buffer, 100 µl Proteinase K, 8.9 ml ddH20 
 
Buffers for SDS-PAGE and Western blotting 
 
SDS gel buffer   3 M Tris, 0.3% SDS, pH 8.4 adjusted with HCl 
Native gel buffer  3 M Tris, pH 8.4 adjusted with HCl 
Anode buffer   200 mM Tris, pH 8.9 
Cathode buffer   100 mM Tris, 100 mM Tricine, 0.1% SDS, pH 8.25 
Transfer buffer   50 mM Tris, 40 mM Glycine, 20% Methanol, 0.03 % SDS 
4x SDS Sample Buffer  300 mM Tris, 40% Glycerine, 10% SDS, 0.04% Bromphenol blue,  
pH 8.2; added freshly: 500 mM β-mercaptoethanol 
Ponceau S    0.1 % Ponceau S, 5 % Acetic acid 
Stripping buffer  20 mM Tris.HCl, 2% SDS, 100 mM β-mercaptoethanol, pH 6.7 
Coomassie Staining solution 0.25 % Brilliant Blue 250G, 10 % Glacial acetic acid, 45 % Methanol 
Destaining solution  10% Acetic acid, 45 % Methanol 
 
Buffers for preparation of chemical competent cells 
 
TFBI 100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 15% 
Glycerol, pH 5.8, sterile-filtered 





Solutions for X-Gal staining 
 
Fixing solution   PBS, 2% PFA, 0.2% Glutaraldehyde 
X-Gal staining solution  5 mM K3[Fe(CN)6], 5 mM K4[Fe(CN)6], 2 mM MgCl2,  
1 mg/ml X-Gal diluted in PBS 
2.1.4 Chemicals 
With exception of the chemicals listed below, all reagents mentioned in this work were obtained from 
the Carl Roth GmbH and of highest quality necessary for the intended use.  
Name Vendor 
Adenosin triphosphate (ATP) Thermo Scientific 
Benzonase Novagen 
n-octyl-beta-D-glucopyranoside (Beta OG) Qiagen 
Big Dye ABI 
Brijj 35 Sigma-Aldrich 
CHAPS Sigma-Aldrich 
DMEM Gibco 
dNTP mix, 10 mM Thermo Scientific 
ECL Solution Thermo Scientific 
EDTA Serva 
Ethidium bromide Sigma-Aldrich 
Fetal Calf Serum (FCS) Biochrom 
L-Glutamin Invitrogen 
HEPES Biochrom 
Hydrogen peroxide Merck 
Lysozyme Sigma-Aldrich 
Non-fat dry milk powder Sucofin 
Nonidet P-40 (NP-40) Sigma-Aldrich 
Polyethylenimine, linear 25 kDa (PEI) Polysciences, Inc 
Proteinase K Qiagen 
Nuclease Free Water Promega 
RPMI 1640 Gibco 




2.1.5 Commercial reagents/kits 
Name Vendor 
BCA Protein Assay Kit Thermo Scientific 
Bradford protein assay dye Bio-Rad 
Blood and Tissue Genomic DNA Extraction Kit Qiagen 
Invisorb Spin Plasmid Mini Kit Two Invitek 
Invisorb Spin DNA Extraction Kit Invitek 
Plasmid Midi/Maxi-Kit, EndoFree Qiagen 





2.1.6 Instruments and equipment 
Name Vendor 
Accu Jet Pipette boy NeoLab 
Avanti J-20XP Centrifuge Beckmann-Coulter 
Äkta Explorer 10s FPLC GE Healthcare 
Axiovert 200 Zeiss 
Biacore X100 GE Healthcare 
ChemoCam Imager Intas 
Centrifuge 5415D Eppendorf 
Centrifuge 5805R Eppendorf 
Discovery Comfort Multichannel pipettes  Abimed 
ELISA-Reader Tecan/ThermoScientific 
ELISA Washer Tecan 
SkanWasher300 Skatron Instruments 
EliSpot reader AID 
FACSCalibur BD Biosciences 
GloMax-Multi Microplate Reader Promega 
Guava easyCyte 5HT Flow Cytometer Millipore 
Helios GeneGun BioRad 
Mastercycler pro S Eppendorf 
MxPro3005 qPCR System Agilent Technologies 
Ovation Electronic Pipettes VistaLab Technologies 
NanoDrop ND-1000 Spectrophotometer PeqLab 
SDS-PAGE system (Standard) Höfer/Biometra 





ChemoStar gel documentation  Intas 
Cell^F Imaging Software Olympus 
LaserGene Sequence Analysis Suite DNAStar 
FlowJo Treestar, Inc 
PredictProtein Rost et al., (2004) 
 
 
2.1.8 Primer and oligonucleotides 
Primer Name Sequence 
PFV-ED-Xa fwd 5'-aggatctggctctggatctggtatcgagggaagggatattaatgatgaaaactta-3' 
PFV-ED rev 5'-atactcgagttagtgatggtgatggtgatggtggtgaggctttaagtatcccaagag-3' 
FFV-TMop-Xa fwd 5'-aggatctggctctggatctggtatcgagggaagggatctgaacgatcagaaactg-3' 
FFV-TMop rev 5'-atactcgagttagtgatggtgatggtgatggtggtgcgcggtgccaaaaattccacc-3' 
FFV Bet fwd 5'-atggcttcaaaatacccggaagaaggacca-3' 
FFV Bet rev 5' -tcatctgactctgaagctggtgcagccggctag-3' 




Primer Name Sequence 
FFV Bet E1 rev 5'-tataagctttagctcagcagctgacgtgc-3' 
FFV Bet E2 fwd 5'-tcaggttcagctggtgctggcgcaggtggaggccaggaaaaaaacgaacaggaactgctggaactggat-3' 
FFV Bet E2 rev 5‘-tataagctttaccacagccagttggtaatatt-3' 
FFV BetSeq1 fwd 5'-cgccgctacacttactaaaac-3' 
FFV BetSeq1 rev 5'-cccaaaggggatcatgttcag-3' 
NS005 fwd 5'-aaaatttatttgctttgtgagcg-3' 
NS006 rev 5'-ccagatggagttctgaggtca-3' 
1.2 fwd 5'-caagaaaagaatgaacaagaattattgga-3' 
1.2 rev 5'-ttccattgcatccagctc-3' 
1.3 rev 5'-cattgcatccagctcagc-3' 
2.1 fwd 5'-gaattacaggccctggaggc-3' 
2.1 rev 5'-agacaataattgtctggcctgtac-3' 
3.1 fwd  5'-ttacaggccctggaggc-3' 
Primer I 5'-ataaccggtacacccaagacggatcctactcg-3' 
Primer II 5'-ctagtgatggtgatggtgatggctagcttcagagtcagatgactcagatgt-3' 
Primer III 5'-gctagccatcaccatcaccatcactagaaagcctgaatttacctggattatgca-3' 
Primer IV 5'-atatgcatgccgaaagttgttcttctcttctaggttc-3' 
Primer V 5'-atagctagcggtgctggcgcaggtggaggc-3' 
Primer VI 5'-caggtaaattcaggctttttaccacagccaatttgttatg-3' 
Primer VII 5'-tggctgtggtaaaaagcctgaatttacctggat-3' 




2.1.9 Primer and probes for quantitative real-time PCR 
Primer Name Sequence 
MM007* 5'-caaatggtcgctggagaat-3' 
MM008* 5'-gcccagaaaccattggataa-3' 
MM009 (Probe) 5'-[6FAM]-tgatagctgtacaaaatcaacactcgtatgg-[BHQ1]-3' 
feline GAPDH fwd 5'-caaattccacggcacagtc-3' 
feline GAPDH rev 5'-tactcagcaccagcatcacc-3' 
feline GAPDH (Probe) 5'-[HEX]-ggctgagaacgggaaacttgtcatcaatg-3' 
PFV fwd 5'-cttcaacctttgctgaatg-3' 
PFV rev 5'-taatacagggctataggtgt-3' 









2.1.10 Plasmid vectors and molecular clones 
Plasmid Description Source/Reference 
pQE-30 Xa 
Prokaryotic expression vector for expression of N-terminal 
His-tagged proteins under control of the T5 promoter. 
Cleavage of His-tag possible through Factor Xa cleavage 
site. Used for production of FFV Bet and Bet/HIV-1 
hybrids as well as FPPR/MPER loop antigens. 
Qiagen, Germany 
pGEX-KG 
Prokaryotic expression vector for expression of N-terminal 
GST-tagged proteins under control of the pTac promoter. 
Encodes the LacIq repressor and a Factor Xa cleavage site 
for removal of the GST fusion partner. Used for expression 
of FFV and PFV TM proteins. 




Prokaryotic expression vector encoding a GST-tagged 
form of the feline APOBEC-A3Z2b protein. Used to 
evaluate Bet protein integrity after refolding. 
D. Slavkovic, DKFZ 
(207) 
pNL4.3 
Full length, replicating and infectious molecular clone of 
HIV-1. Used for production of HIV-1 viral supernatants. 
NIH Reagent Program 
(208) 
pCF-7 
Full length, replicating and infectious molecular clone of 
FFV in which the 5’ LTR was exchanged by a CMV 
promoter to increase genetic stability in bacteria. Used for 
production of FFV viral supernatants and subcloning of 
HIV-1 sequences in frame to Bet. 
M. Löchelt, DKFZ 
(209) 
pEGFP-N3 
Eukaryotic expression plasmid encoding enhanced GFP 
under control of the CMV promotor. Used during 
transfections to estimate transfection efficiency. 
Clonetech, USA 
pHSRV13 
Full length, replicating and infectious molecular clone of 
the PFV (SFVCpz). Used to produce supernatants of PFV. 
M. Löchelt, DKFZ 
(210) 
pBC12-Env 
Eukaryotic expression vector encoding the wildtype FFV-
FUV Env protein under control of the CMV promoter. 
M. Löchelt, DKFZ 
(211) 
pBC12-EnvG2 
Based on pBC12-Env. Encodes the FFV-FUV Env protein 
silently mutated in the Env splice donor and acceptor sites 
to prevent splicing of the MSD domain. Contains additional 
restriction sites: BspE1, eight nucleotides upstream of the 
splice donor site; SgrAI, 18 nucleotides downstream of the 
splice donor. BlpI and Bst1107I sites flanking the FPPR 
region. Used for introduction of HIV-1 MPER and FPPR 
and production of wildtype subviral particles. 
A. Bleiholder, DKFZ 
pBC12-Bet 
Eukaryotic expression vector encoding the full length FFV 
Bet protein under control of the CMV promoter. Used as 
DNA template for cloning of prokaryotic Bet expression 
vectors. 
D. Slavkovic, DKFZ 
pMAT 
Synthetic plasmid synthesised by GeneArt. Encodes the 
longest FPPR/MPER loop construct F0-M0. Used for 








Two synthetic peptides synthesised by GeneCust, Luxembourg were used in this study. HIV-1 E1 
comprising the FPPR residues N-AAGSTMGAASMTLTVQARLLLSKKKK-C and HIV-1 E2 
consisting of the MPER sequence N-KKKKEQELLELDKWASLWNWFNITNWL-C. Peptides had a 
purity of more than 90% and were resuspended to 1 mg/ml in DMSO before further dilution as required. 
 
2.1.12 Protein and DNA ladders 
Page Ruler protein ladder, PeqLab, Germany 
Page Ruler Prestained protein ladder, PeqLab, Germany 
GeneRuler DNA Ladder Mix, ready to use, Thermo Fisher, Germany 
GeneRuler 1 kb DNA Ladder, ready to use, Thermo Fisher, Germany 
 
2.1.13 Media for eukaryotic cell culture 
DMEM Dulbecco’s Modified Eagle Medium, supplemented with 10% [v/v] FCS, 2 mM 
L-Glutamine, 10 mM HEPES and 5 mM Penicillin/Streptomycin. 
  
RPMI 1640 RPMI 1640, supplemented with 10% [v/v] FCS, 2 mM L-Glutamine, 10 mM 
HEPES and 5 mM Penicillin/Streptomycin.  
 
2.1.14 Eukaryotic cell lines 
 
HEK 293  Human adherent cell line obtained by transformation of human embryonic kidney cells 
with sheared Adenovirus 5 (212). Propagated in DMEM medium. ATCC Cat# CRL-
1573. 
  
HEK 293T Highly transfectable derivative of the HEK293 cell line stably expressing the Simian 
Virus 40 (SV40) Large T antigen for episomal maintenance of plasmids containing the 
SV40 origin of replication (213). Cells were cultured in DMEM medium. ATCC Cat# 
CRL-11268. 
  
C8166  A lymphotrophic T cell line derived by fusion of primary umbilical cord blood cells 
with HTLV-1 producing cells from an adult T cell leukaemia lymphoma patient. The 
cell line carries, however, does not express the HTLV-1 genome. It promotes high level 
replication of HIV-1 with simultaneous syncytia formation which can be used to assess 
neutralising capacity of antisera or antibodies. The cell line was obtained through the 
AIDS Research and Reference Reagent Program Cat# 404, from Dr. Robert Gallo and 







TZM-bl Highly HIV-1, SIV and SHIV permissive indicator cell line derived from HeLa cells, 
transduced to stably express CD4 and CCR5 receptors as well as reporter genes for 
firefly luciferase and β-galactosidase under control of the HIV-1 LTR. Upon infection, 
expression of the transactivator Tat drives expression of reporter genes allowing 
quantification of infection (214, 215). Propagated in DMEM medium. The cells were 
obtained through the NIH AIDS Research and Reference Reagent Program (Cat# 8129): 
TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. 
 
CRFK  Crandell-Reese feline kidney cells, derived from a primary kidney cell culture of a 
domestic cat (Felis catus). Has high susceptibility for and promotes high level 
replication of feline viruses including FFV (216). Used for propagation of FFV. 
Cultured in DMEM medium. The cell line was kindly provided by Martin Löchelt 
(DKFZ, Heidelberg). 
  
FeFAB  Indicator cells based on the CRFK cell line. Express the β-galactosidase reporter gene 
under control of the FFV LTR promoter. Upon infection, expression of the 
transactivator Tas drives expression of the reporter gene allowing quantification of 
infection. Used for determination of virus titer and FFV neutralisation assays (217). 
Cultured in DMEM supplemented with 0.5 µg/ml geneticin. The cell line was kindly 
provided by Martin Löchelt, (DKFZ, Heidelberg) 
 
2.1.15 Media and recipes for prokaryotic cell culture 
LB  10 g tryptone, 5 g yeast extract, 170 mM NaCl, pH 7.5 
2YT  16 g tryptone, 10 g yeast extract, 100 mM NaCl, pH 7.4 
TB   12 g tryptone, 10 g yeast extract, 0.4% glycerol, 15 mM KH2PO4, pH 7.4 
SOC  20 g  tryptone, 5 g  yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2,  
10 mM MgSO4, 20 mM glucose, pH 7.2 
 
2.1.16 E. coli bacterial strains 
DH5α  Recombinase and endonuclease deficient bacterial strain for standard cloning 
applications. Purchased from Invitrogen Life Technologies. Genotype: F- 
Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44 
thi-1 gyrA96 relA1 λ-. 
 
Top 10  Recombinase and endonuclease deficient bacterial strain for cloning purposes. 
Purchased from Invitrogen Life Technologies. Genotype: F- mcrA Δ( mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) 
endA1 nupG. 
 
XL1-Blue Recombinase and endonuclease deficient bacterial strain for cloning purposes. 
Purchased from Agilent Technologies. Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)]. 
 
ER2925 Methylation deficient bacterial strain used for cloning with methylation sensitive 
restriction sites. Obtained from New England Biolabs. Genotype: ara-14 leuB6 fhuA31 
lacY1 tsx78 glnV44 galK2 galT22 mcrA dcm-6 hisG4 rfbD1 R(zgb210::Tn10)TetS 





BL21  Standard expression strain deficient in lon and ompT proteases. Obtained from 
Novagen. Genotype: F– ompT hsdSB(rB–, mB–) Ion gal dcm (DE3). 
 
SCS-1/ Parental SCS-1 strain from Agilent Technologies transformed with the pSE111  
pSE111 plasmid encoding the lacIq repressor and the argU gene for a rare arginine tRNA as well 
as Kanamycine resistance (218). This strain was kindly provided by Jürgen Kreuzberger 
(RKI, Berlin).  
 
Overexpress  Enhanced BL21 derivatives for expression of toxic and membrane proteins. Purchased 
C41, C43 from Lucigen, USA. Genotype as BL21, with unknown mutations. 
 
Rosetta 2 Enhanced BL21 derivative encoding seven rare t-RNAs on the plasmid pRARE2 to 
avoid codon bias with eukaryotic genes. Purchased from Novagen. Genotype as BL21. 
 
Shuffle T7  Enhanced BL21 derivative with mutations in reduction pathways to allow disulphide 
Express formation in the cytoplasm of E. coli. Constitutively expresses the chaperone DsbC 
isomerase for disulphide reshuffling. Purchased from New England Biolabs. Genotype: 
MiniF lysY (CamR) / fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal λatt::pNEB3-r1-
cDsbC (SpecR, lacIq) ΔtrxB sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-





2.2 Molecular biological methods 
 
2.2.1 Isolation of plasmid and genomic DNA 
For purification of up to 50 µg of plasmid DNA the Invisorb Spin Plasmid Mini Kit Two with 2-4 ml 
overnight cultures of bacteria was used. Large scale preparations of 100 to 500 µg DNA was performed 
with Midi- and MaxiPrep columns with cells pelleted from culture volumes of 100 or 400 ml, 
respectively. In case of DNA used for Gene Gun immunisation experiments, utilising the EndoFree 
Plasmid Maxi Kit assured removal of endotoxins from the sample. In all cases, DNA was extracted from 
bacterial cloning strains to obtain the highest DNA quality possible. Isolation of genomic DNA from 
infected cells was performed using the Blood and Tissue DNA Extraction Kit following the 
manufacturer-provided protocol. 
 
2.2.2 Agarose gel electrophoresis and DNA extraction 
Agarose gel electrophoresis was applied for various analytical and preparative tasks. In concentrations 
adapted to the individual experiment gels were made by dissolving agarose in 1x TAE-Buffer and 
boiling until a homogenous solution developed. After cooling and addition of ethidium bromide the 
entire mix was poured in a horizontal gel chamber. When polymerised, DNA samples were diluted with 
DNA loading buffer and separated by applying a current of 120 Volts. Gels were documented using a 
UV transilluminator system and ChemoStar software. To extract DNA, fragments of interest were 
excised from the gel under UV exposure, molten in solubilisation buffer at 52°C and bound to micro-
columns supplied in the Invisorb Spin DNA Extraction Kit . After wash and ethanol removal, DNA was 
eluted using 30-50 µl of nuclease free water. 
 
2.2.3 Restriction digestion and DNA modifications 
Restriction digestion was performed with FastDigest enzymes obtained from Thermo Scientific, 
Germany. DNA concentration in analytical as well as preparative digestions was adjusted to 0.05 µg/µl 
and 1-5 units of the required enzyme(s) per microgram DNA to assure optimal reaction conditions. 




inserts was achieved with shrimp alkaline phosphatase or T4 polynucleotide kinase following the 
manufacturer provided protocols (Thermo Scientific, Germany). Similarly, 5’ fill-in reactions for 
subsequent blunt-end cloning was carried out with Klenow-Fragment polymerase as recommended by 
the supplier (Thermo Scientific, Germany). 
 
2.2.4 Preparation of chemical competent cells 
Competent cells were prepared using cultures grown in LB medium without antibiotics overnight and a 
Qiagen protocol (Ref). Briefly, stationary bacteria were diluted 1:100 into fresh LB medium and grown 
to an OD600 of 0.6. After pelleting (4000 g, 5 min, 4°C), cells  were resuspended in ice-cold buffer TFB1 
and incubated on ice for 90 min. TFB1 buffer was removed subsequently by centrifugation (4000 g, 5 
min, 4°C) and decanting and the pellet resuspended with cold buffer TFB2. Cells were then immediately 
aliquoted into sterile PCR tubes, snap-frozen in liquid nitrogen and stored at -80°C until use. 
 
2.2.5 Ligation and transformation of chemical competent bacteria 
Solutions containing appropriately prepared vector and DNA inserts at a molar ratio of 1:1 to 1:3 (100-
200 ng DNA in total) were supplied with 10x T4 ligase buffer and 1 µl T4 ligase in 20 µl reaction 
volumes and incubated at RT for 1 h or alternatively overnight at 16°C. 5 µl of the reaction mixture was 
taken for transformation of 50 µl chemical competent cells by incubating the DNA/bacteria mixture for 
20 min on ice. After heat shock (30 s at 42°C) cells were cooled on ice for 2 min before addition of 300 
µl SOC medium and further incubation at 37°C to allow for expression of antibiotic resistance promoting 
genes. The entire mix was then plated on LB plates containing appropriate antibiotics and grown further 
at 37°C until colonies appeared. 
 
2.2.6 Preparation of glycerol stocks 
Standard glycerol stocks were prepared by shortly mixing bacterial overnight cultures with sterile 50% 
glycerol at equal volumes followed by snap-freezing in liquid nitrogen. For glycerol stocks of expression 




of 0.6 before glycerol addition and freezing to assure highest viability and an exponential growth phase. 
All stocks were kept at -80°C for storage. 
 
2.2.7 Colony PCR 
To screen for positive clones after ligation and transformation into bacteria, colony PCR was applied. 
Individual clones were picked using a pipet tip, set down on a numbered agar plate as backup and the 
residual bacteria resuspended in the PCR reaction mix that contained appropriate primers for insert 
detection. Initial denaturation was extended to ten minutes to assure disintegration of bacteria and DNA 
release. A representative set-up for this type of PCR is given in Table 4 
 
Table 4. Master mix for Colony-PCR           Cycler conditions 
         
            94°C, 10 min 
            94°C, 40 s  →  Denaturation 
            54°C, 30 s  →  Annealing 
            72°C, 60 s  →  Elongation 
            72°C, 2 min  





2.2.8 PCR cloning  
Most of the expression plasmids described in this work were generated through amplification of target 
sequences from available plasmids and subsequent subcloning into a target vector. For these purposes, 
Platinum Pfx proof-reading polymerase (Invitrogen, USA) was used to prevent introduction of mutations 
during PCR. In most cases, a prior PCR optimisation step testing several annealing temperatures and 
MgSO4 concentrations was performed to find optimal conditions for high-yield and specific 





Total 15 µl 
final 
concentration 
10 x HRS2 buffer 1.5 µl 1 x 
MgCl2 (25 mM) 1.2 µl 2 mM 
dNTP’s (10 mM) 0.3 µl 0.2 mM 
3’-Primer (10 µM) 0.3 µl 0.2 µM 
5’-Primer (10 µM) 0.3 µl 0.2 µM 
DNA 1 colony - 
Segenetic polymerase 
(2.5 U/µl) 
0.2 µl 0.033 Units 





Table 5. Master mix for proof-reading-PCR           Cycler conditions 
         
            94°C, 10 min 
            94°C, 40 s     →  Denaturation 
            54°C, 30 s     →  Annealing 
            68°C, 2 min  →  Elongation 
            72°C, 2 min  




To obtain truncated version of the described HIV-1 E1-E2 loop antigens, the initial pMAT vector 
synthesised by GeneArt was mutated by amplification of the full-plasmid with appropriate primers. The 
Pfx PCR used here was identical to that described above. However, to allow self-linearisation of the 
obtained amplicons, phosphorylated primers and lower amounts of DNA during ligation were needed. 
Table 6 and Table 7 summarise protocols for both methods. 
 
 Table 6. Mixture for primer phosphorylation  Table 7. Self-circularisation of linear DNA 
Primer (100 pmol/µl) 0.9 µl  DNA 10-20 ng 
10 x T4 PNK buffer A 0.9 µl  10 x T4 ligase buffer 2 µl 
10 mM ATP 0.9 µl  T4 ligase (5 U/ml) 1 µl 
T4 PNK 0.8 µl  ddH2O ad 20 µl 
ddH2O ad 10 µl   
 
 
2.2.9 Quantitative real-time PCR for detection of FFV and PFV proviral DNA 
A sensitive qPCR assay for detection of proviral FFV DNA from infected CRFK cells was established 
by designing primers and a fluorescent probe amplifying a short 156 bp fragment from a conserved 
region in the pol reading frame (nt 2478-2633, NC001871). Reaction conditions were optimised to reach 
highest sensitivity by short amplification times. When FFV plasmid-spiked cell lysates were used as 
template, the detection limit of this qPCR reached down to 10 FFV copies and was linear over a several 
logs of plasmid concentrations (Fig. 12). The sensitivity in FFV neutralisation assays for which this 
qPCR was developed for (section 2.5.5) was lower (~20 copies, not shown), probably due to the presence 
of inhibiting substances in cell lysates. In a separate qPCR, feline GAPDH was amplified as reference 
Total 50 µl 
final 
concentration 
10 x Pfx buffer 5 µl 1 x 
MgSO4 (50 mM) 1-3 µl 1-3 mM 
dNTP’s (10 mM) 1.5 µl 0.3 mM 
3’-Primer (10 µM) 1.5 µl 0.3 µM 
5’-Primer (10 µM) 1.5 µl 0.3 µM 
Template DNA variable 10-100 ng 
Pfx polymerase  (2.5 U/µl) 0.4 µl 0.016 Units 





gene with an amplicon size of 120 bp using the same cycling conditions as for FFV. The qPCR for 
detection of PFV provirus was developed and kindly provided by Rico Blochmann (RKI, Berlin). 
Reaction set-up and cycling conditions for both PCRs are given in Table 8 and Table 9. 
 
Table 8. Master mix for FFV qPCR           Cycler conditions 
         
            95°C, 10 min 
            95°C, 30 s     →  Denaturation 
            54°C, 40 s     →  Annealing 
            68°C, 1 min  →  Elongation 





Fig. 12. Efficiency of the qPCR for detection of FFV proviral DNA. Left panel: Amplification plots of a FFV qPCR assay performed with the 3 
µl of cell lysate from non-infected CRFK cell spiked with serially diluted pCF-7 plasmid DNA corresponding to the number of genome copies 
as indicated. Measurements were performed here in duplicates. Right panel: Plotting of FFV genome copies versus Ct values calculated from 
amplification plots shows linear amplification of FFV DNA over several logs. The regression function and the regression coefficient is given. 
 
 
Table 9. Master mix for PFV qPCR           Cycler conditions 
         
            95°C, 8 min 
            95°C, 1 min   →  Denaturation 
            58°C, 1 min    →  Annealing 
            72°C, 15 s      →  Elongation 
            4°C, ∞ 
 
 
Total 25 µl 
final 
concentration 
10 x PCR-buffer 2.5 µl 1 x 
MgCl2 (25 mM) 1 µl 1 mM 
dNTP’s (10 mM) 0.6 µl 0.25 mM 
3’-Primer FFV (10 µM) 0.9 µl 0.3 µM 
5’-Primer FFV (10 µM) 0.9 µl 0.3 µM 
Probe FFV pol (10 µM) 0.5 µl 0.15 µM 
CRFK cell lysate 3 µl - 
Amplitaq Gold (1 U/µl) 0.25 µl 0.25 Units 
ddH2O 15.4 µl  
Total 25 µl 
final 
concentration 
10 x PCR-buffer 2.5 µl 1 x 
MgCl2 (25 mM) 2 µl 1 mM 
dNTP’s (10 mM) 0.6 µl 0.25 mM 
3’-Primer PFV (10 µM) 0.5 µl 0.3 µM 
5’-Primer PFV (10 µM) 0.5 µl 0.3 µM 
Probe PFV pol (10 µM) 0.5 µl 0.15 µM 
BHK cell lysate 3 µl - 
Amplitaq Gold (1 U/µl) 0.2 µl 0.2 Units 
ddH2O 15.4 µl  









































2.3 Protein chemical methods 
 
2.3.1 Determination of protein concentration 
Protein concentration was determined by using (i) the absorbance of the solution at 280 nm together 
with the molar extinction coefficient or correction factors for 0.1% solutions, both calculated form the 
primary amino acid sequence by ProtParam (http://web.expasy.org/protparam) (ii) a commercial 
microplate BCA assay by incubating samples along with a BSA standard with BCA solution for 30 min 
at 37°C and read-out at 562 nm (iii) a commercial Bradford assay by mixing samples or BSA standard 
with Bradford solution followed by spectrometric reading at 595 nm. Selection of the protein assay was 
dependent on the amount of sample available and the presence of substances that might interfere with 
absorbance or assay sensitivity (DTT, Urea, etc). 
 
2.3.2 SDS-PAGE and native PAGE  
For separation of proteins, polyacrylamide electrophoresis was performed as described previously (219). 
Briefly, separation gels in concentrations depended on the size of proteins to be separated (8-12%) were 
prepared and poured in a vertical gel chamber and overlaid with ethanol. After polymerisation the 
ethanol was discarded, a stacking gel (4%) poured on top of the separation gel and a comb added for 
later addition of the samples. After mixing with sample buffer, proteins were boiled shortly at 90°C for 
5 min before loading onto the gel. For Native PAGE, SDS in gel and running buffers was omitted, 
samples resuspended in native loading buffer containing no 2-mercaptoethanol (Bio-Rad, Germany) and 
loaded without prior boiling.  
 
2.3.3 Coomassie blue staining 
Gels from SDS-PAGE or native PAGE were stained by incubation  in Coomassie blue solution for 20 
min. Successive dye was recovered, the gel shortly rinsed in distilled water as a first wash and then 






2.3.4 Protein expression optimisation and solubility testing 
To optimise protein production, expression vectors were transformed into selected bacterial strains, and 
grown overnight at 37°C. From each plate, two colonies were selected and grown as day cultures until 
an OD600 of 0.6 before storing as glycerol stocks. From these stocks overnight cultures were grown in 
LB medium. On the next day, each well of a 96 deep well plate containing 1 ml of either LB, 2YT, TB 
or SOC medium and antibiotics was inoculated with 100 µl of the stationary overnight to reach a final 
OD600 of 0.2 and grown for 3 h at 37°C. For induction, cultures were adjusted to 0.1 and 1 mM IPTG in 
parallel to non-induced controls. Empty control vectors were induced with the highest IPTG 
concentration only. After additional 3 h incubation at indicated temperatures, cells were pelleted by 
centrifugation for 15 min at 3700 rpm in an Eppendorf plate centrifuge, lysed by three successive 
freeze/thaw cycles in liquid nitrogen and subsequently resuspended in 100 µl lysis buffer (PBS, 0.1 
mg/ml lysozyme, 50 U/ml benzonase). For overall expression analysis 10 µl of the total cell lysate was 
analysed by SDS–PAGE  and Coomassie blue staining. To assess the levels of soluble expressed protein, 
total lysates were subjected to sonification (2 x 5 pulses with 40% DC, level 4), centrifuged at 16.000 g, 
4°C for 20 minutes and supernatants analysed for the presence of the respective protein. 
 
 
Fig 13. Strategy to optimise protein expression in 96 deep well plates. Four bacterial strains (strains 1–4), three growth media (M1, M2, 
M3), three IPTG concentrations (grey arrows) and two transformants (clone 1, clone 2) along with the empty vector as control were used. 
One plate was intended for every temperature to be investigated. The design also allowed easy transfer to SDS–PAGE by multichannel 







2.3.5 Large scale expression in E. coli  
After suitable parameters were found by expression optimisation, conditions were scaled-up accordingly 
for large-scale production (Table 10). Production was performed in 5 L flasks containing 2 L of medium 
and inoculated with ~100 ml overnight culture grown in LB medium to achieve a final OD600 of 0.2.  
 













pGEX-FFV-TMop-His Rosetta 2 1 mM 37°C 3 h TB denaturing 
pGEX-PFV-TM-His Rosetta 2 1 mM 37°C 3 h TB denaturing 
pQE-Bet SCS-1 0.5 mM 20°C 2 h TB 
non-
denaturing 




SCS-1 0.5 mM 37°C 3 h 2YT denaturing 






SCS-1 1 mM 37°C 3 h TB denaturing 
 
 
2.3.6 Detergent screening 
To test if detergents could solubilise insoluble proteins or prevent their co-precipitation with E. coli 
membrane fragments, non-ionic and ionic detergents were used for a detergent screening. Detergents 
were added at 1x or 5x of their critical micelle concentration directly to the cell lysis buffer before 
sonification or to the pelleted material after cell disruption and centrifugation. Incubation times were at 
least 2 h after mixing to assure complete extraction. Subsequently, lysates were spun (16.000 g, 4°C) to 






2.3.7 Purification of recombinant proteins 
Purification of FFV and PFV TM proteins by on-column refolding or using a sarcosyl extraction and 
refolding protocol has been already described in great detail (220, 221). Similarly, purification of Bet 
and Bet/HIV-1 hybrid proteins has been described elsewhere (222). Production of FPPR/MPER loop 
antigens followed the sarkosyl extraction and refolding protocol established for the FV TM proteins. 
Purification of GST and GST-feA32Zb using glutathione beads (GE Healthcare, Germany) was 
performed using the manufacturer protocol with subsequent gel filtration in PBS for final purification. 
Typical yields were 15 and 4-5 mg/L for GST and GST- feA32Zb, respectively and purity reached ~80-
90% as judged by SDS-PAGE analysis. 
 
2.3.8 Refolding screening for FFV Bet 
Denatured Bet protein from affinity chromatography at 2 mg/ml was reduced with 20 mM TCEP for 1 h 
at RT and complete reduction monitored by analytical gel filtration. After desalting to buffer D (8 M 
Urea, 50 mM Tris, 300 mM NaCl, pH 8.5) with a HiPrep 26/10 desalting column (GE Healthcare, 
Germany), refolding was immediately initiated by 1:20 dilution in 50 mM Tris, pH 8.5 or in the same 
buffer supplied with various co-solvents (0.5 M L-arginine, 20% Glycerol, 0.3% PEG 6000, 0.3 M 
Sucrose, 0.05% N-laurylsarcosine). Additionally, individual buffers were adjusted to different 
concentrations of reduced and oxidised forms of Glutathione (0/0, 3/0.3, 3/0.5, 3/1, 3/3, 1/3, 0.5/3, 0.3/3 
mM GSH/GSSG). Microplates were then incubated for 48 h at 4°C and samples spun at 16.000 g for 20 
min before analysing supernatants for APOBEC ligand binding. Therefore, Bet refolded under the 
various conditions was further diluted 1:20 in PBS and 500 ng captured on 96 well His-Select HS Ni-
NTA plates (Sigma Aldrich, Germany). Plates were washed with PBS-T (PBS, 0.05% Tween 20) and 
then incubated for 2 h at RT with 500 ng of purified GST or GST-feA3Z2b (207) diluted in PBS-T 
containing 0.05% BSA. After 3 washing steps, plates were probed with an goat anti-GST antibody 
detected by an anti-goat-IgG-HRP conjugate, each applied for 30 min at RT and diluted in PBS-T 
containing 0.05% BSA. Plates were developed with a colorimetric OPD substrate (1 mg/ml in PBS with 
0.2% H2O2) for 10 min. The reaction was stopped with 5 N H2SO4 and absorbance at 492 nm measured 





2.3.9 Protein desalting and buffer exchange 
After purification of recombinant proteins, transfer to a final formulation buffer, in most cases PBS, was 
achieved by FPLC-assisted desalting on HiTrap 5 ml (GE Healthcare, Germany) or preparative HiTrap 
26/10 desalting columns. Alternatively, dialysis tubes (Serva, Germany) with a MWCO suitable for the 
respective protein were loaded with sample and incubated overnight in in large vessel (200-500x sample 
volume) and the buffer changed on the next day again to ensure complete buffer exchange. 
 
2.3.10 Gel filtration 
Final purifications or analysis of the oligomeric state of proteins was performed on Superdex 75 or 
Superdex 200 HR 10/300 columns (GE Healthcare, Germany). As protein standards BSA (66 kDa), 
Ovalbumin (43 kDa) and Lysozyme (17 kDa) were used for column calibration and run under identical 
conditions (elution buffer, flow rate, sample volume) as the sample to be analysed. 
 
2.3.11 CD spectroscopy 
Purified proteins were measured at the Leibniz Institute for Molecular Medicine (FMP) in a Jasco 720 
spectropolarimeter in 0.01 cm quartz cuvettes with 0.1 nm dot pitch and 50 nm/min scanning speed in 
the range of 260-190 nm. Ellipticity θ was calculated with obtained CD data in millidegrees, mean 
residue weights of 114.4, 111.3, 113.5 and 111.9 g/mol and protein concentrations of 0.21, 0.28, 0.20 
and 0.27 mg/ml for the GST-TM and TM proteins of FFV, and the GST-TM and TM proteins of PFV, 
respectively. In case of the FFV Bet protein mean residue weights of 114.6 g/mol and a protein 
concentration of 0.3 mg/ml was used. Spectra were means of ten individual measurements performed at 
room temperature and subtracted by the mean spectrum obtained with buffer only. For estimation of 
secondary structures, CD data were analysed with SELCON3, CDSSTR and CONTINLL programs 
which are part of the CDpro software package (223, 224) using the SMP56 protein reference set which 
includes spectra of 40 soluble and 13 membrane proteins and which is optimised for interpretation of 
spectra in the range of 190-240 nm (225, 226). Amino acid based secondary structure predictions were 





2.3.12 Surface plasmon resonance 
Surface plasmon resonance experiments were performed on a Biacore X100 device with anti-human 
IgG-Fc specific antibodies immobilised on CM5 chips (GE Healthcare, Germany). 2F5 or 4E10 in 50 
mM NaH2PO4, 300 mM NaCl, pH 8.0 were captured at 300-500 response units (RU) on flow cell 2 and 
three increasing concentrations of fusion proteins diluted in 50 mM NaH2PO4, 300 mM NaCl, pH 8.0 
were injected on both flow cells. After regeneration with 10 mM glycine, pH 2.0 and antibody 
recapturing, blank resonance was measured by three injections of dilution buffer. Sensograms were 
reference cell subtracted and blank normalised values from at least two repeated experiments. Curves 
were fitted using the 1:1 binding algorithm and quality of fitting was checked by assuring KD values in 
the range of measured protein concentrations, plausible Rmax values, small 2 values as well as residuals 
within recommended borders. 
 
2.4 Immunological methods 
 
2.4.1 Western blotting and membrane stripping 
PVDF membranes (Milipore, USA) were activated in methanol and transfer buffer and placed on a filter 
paper, followed by the SDS gel and another layer of filter paper. The sandwich was assembled in a semi-
dry blotting chamber (BioRad, Germany).  After transfer for 25 min at 20 V, the sandwich was removed 
from the device and even transfer confirmed by staining with Ponceau S solution and destaining with 
distilled water. Afterwards, blocking of unspecific binding sites was achieved by incubation with 5% 
dry-milk dissolved in PBS-T for 1 h at room temperature or overnight at 4°C. Primary antibodies 
prepared in 2.5% milk in PBS-T at dilutions as indicated were incubated on membranes for 1 h at room 
temperature, washed (3x5 min PBS-T) and detected by suitable HRP-coupled secondary antibodies (30 
min). In cases were primary antibodies from different species had to be detected simultaneously, HRP 
coupled to Protein A or G (Invitrogen, USA) was used for detection. After additional washing, blots 




reprobing of membranes, they were incubated in stripping buffer for 1 h at 60°C under rotation, rinsed 
shortly in PBS-T to remove any residual stripping buffer and blocked and probed as above. 
 
2.4.2 ELISA 
If not stated otherwise, purified proteins or synthetic peptides were coated onto ELISA plates at 200 
ng/well by dilution in water or PBS. After attachment overnight at 37°C or 4°C in cases were 
conformational binding should be investigated, plates were blocked with 5% BSA in PBS-T for 1 h at 
37°C and washed once with PBS-T using a ELISA washer. Primary antibodies were added at dilutions 
as indicated and allowed to bind for 1 h at 37°C. After three washing cycles, suitable HRP-labelled 
secondary antibodies were added for 30 min at 37°C. Unbound antibody was removed by seven 
successive washing steps and the plates developed with a colorimetric OPD substrate as before. 
 
2.4.3 Epitope mapping 
Two different types of epitope mapping techniques were applied during this thesis. Initially, PepSpot 
nitrocellulose membranes spotted with the intended peptides and later on PepStar glass chips that bind 
the peptides through an N-terminal spacer/linker on the surface were used. As the latter one are probed 
with fluorescent secondary antibodies, higher sensitivity compared to PepSpot HRP/ECL detection 
system could be achieved. Furthermore, peptides on the glass chips could be spotted in much higher 
density, which in collaboration with JPT allowed the development of microarrays that simultaneously 
map up to 21 sera. In case of the PepSpot membrane the FFV TM ectodomain (amino acids 563-944 
Uniprot Acc. Nr O56861) were spotted as 15mer peptides overlapping by 13 amino acids. On the 
microarrays, the complete FFV-FUV Env protein (15mer peptides, 11 residues overlap, residues 1-982) 
was printed twice per sub-array. Furthermore, these chips contained the extended HIV-1 HXB2 FPPR 
domain comprising amino acids 512-559 and the extended MPER domain comprising amino acids 644-









2.5 Cell culture methods  
 
2.5.1 Transfection of cells using polyethylenimine (PEI) 
For transfection of cells with plasmid DNA, the indicated cell type was seeded 24-48 h in advance and 
supplied with fresh medium directly before treatment. In a 1/10 culture volume, plasmid DNA was 
dissolved in serum-free medium and sterile PEI stock solution (2 µg/µl in PBS) added to yield a 
DNA/PEI ratio of 1:4. After short mixing, the solution was incubated for 15 min at room temperature to 
allow complexes to form. The mixture was then transferred dropwise to the cells by pipetting and evenly 
distributed by gently shaking.  
 
2.5.2 Production of viral supernatants 
For production of FFV or HIV-1 viral supernatants, 293T cells were transfected with infectious 
molecular clones of FFV (pCF-7) or HIV-1 (pNL-4.3), respectively. Two and three days post 
transfection, medium was aspirated and spun briefly at 500 g for 10 min to remove any remaining cells. 
Cleared supernatants were sterile filtered through 0.45 µm filter and then aliquoted and snap-frozen in 
liquid nitrogen for storage at -80°C. Since a strong reduction of viral titres was observed by freezing 
FFV particles compared to storage at 4°C where only a minor decrease in infectivity was observed even 
after 6 months, short-term storage of FFV was usually performed at 4°C.  
 
2.5.3 Virus titration 
For virus titration, aliquots were brought to 37°C in a water bath, serially diluted by twofold dilution 
and 50 µl of virus added in triplicates to indicator cells seeded one day in advance in 96 well plates. In 
case of FFV, CRFK or CRFK based FeFAB cells were used dependent on the read-out method applied. 
Two days after infection, FFV DNA or marker gene expression was measured either by quantitative 
qPCR (see above) or staining with X-gal solution. For the latter one, cells were washed once and fixed 




solution added until colour development (usually within 0.5 to 2 h). Infected cells were counted with an 
ELISPOT reader using the following instrument settings: Intensity MAX: 100, Intensity MIN: 10, 
Gradient MAX: 80,  Gradient MIN: 16, Size MAX: 35, Size MIN: 2, Emphasis: Tiny. HIV-1 titration 
was performed identically on TZM-bl cells. Virus titre was calculated based on the dilution and input 
volume used. Supernatants titrated by qRT-PCR were adjusted to give an ct value of 25 upon infection. 
Viral supernatants containing SIVmac239, used for testing specificity of neutralisation were kindly 
provided by Steve Norley (RKI, Berlin). Titrated supernatants of PFV were kindly provided by Rico 
Blochmann (RKI, Berlin). 
 
2.5.4 Immunofluorescence and flow cytometry 
C8166 cells were infected at a MOI of 0.5 with cell free supernatants obtained from pNL-4.3 transfected 
293T cells and further cultivated for 48 h or 72 h for indirect immunofluorescence or FACS analysis, 
respectively. Non-infected C8166 cells were assayed in parallel to assure the specificity of staining and 
(not shown). Cells were pelleted and washed twice with PBS, fixed by incubation with 2% 
paraformaldehyde in PBS for 15 min and then used either directly for FACS staining or attached to poly-
lysine coated glass slides, dried and rehydrated in PBS overnight. Samples were blocked with 10% 
normal goat serum in PBS for 1 h and then antisera or a pre-immune rat serum as control (all 1:100 in 
3% goat serum, PBS) applied for 1 h. Cells were washed with PBS followed by incubation with a anti-
rat IgG-FITC conjugated secondary antibody, washed again and then either analysed in a FACS Calibur 
flow cytometer or embedded in DAPI containing Vectashield mounting medium (Vector Laboratories, 
USA) for analysis by microscopy. 
 
2.5.5 Neutralisation assays 
To test for the presence of neutralising antibodies, feline CRFK cells or FeFAB cells for FFV or TZM-
bl cells in case of HIV-1 and SIVmac239 were plated one day in advance in 96 well plates (1x104 cells 
per well in 100 µl medium). In a separate plate, serial dilutions of antisera or IgGs starting with 1:10 
were prepared in medium (50 µl/well in triplicates) and challenged with 50 µl of the intended virus 




and incubated for three days. Dependent on the system used, cells were then either analysed by X-gal 
staining and colony counting as described above, or by qPCR. For the latter one, plates were washed 
gently with PBS and frozen overnight to disrupt cells. Lysis was completed by addition of 100 µl of 
Proteinase K solution and incubation at 56°C for 3 h, with subsequent enzyme inactivation at 95°C for 
30 min. For qPCR, 3 µl of cell lysate was pipetted into the qPCR reaction mix. To calculate genome 
copies, a serially diluted plasmid standard mixed with cell lysate from non-infected cells was run in 
parallel. Standard controls comprised infected cells, non-infected cells, and, if available, pre-immune 
sera and positive controls such as bnAb 2F5, 4E10. Dependent on the system used, neutralisation was 
defined as 50 or 70% reduction in provirus detection or number of X-gal positive stained colonies when 
compared to infection control or pre-immune serum as indicated.  
 
 
2.6 Animal experiments 
 
2.6.1 Gene Gun immunisation 
DNA immunisations were performed using the Helios Gen Gun System (Biorad, USA). Therefore, 
plasmid DNA obtained from EndoFree Maxi Kits was precipitated on gold particles. 25 mg of gold 
(diameter 1-3 µm) was mixed with 0.05 M spermidine followed by vortexing and sonication (5 s each). 
Subsequently, 70 µg of plasmid DNA in 100 µl were added to this suspension and mixed well. 
Precipitation of DNA on gold particles was achieved by dropwise addition of 100 µl 1 M CaCl2 during 
vortexing. After 10 min incubation the DNA-loaded particles were collected by centrifugation and the 
supernatant discarded. After three washing steps in 100% ethanol the gold particles were transferred to 
a 15 ml falcon tube prepared to contain 8.75 µl of a 20 mg/ml PVP solution and 3.491 ml 100 % ethanol 
and mixed by vortexing and sonication. The solution was drawn into nitrogen-dried Tefzel tubes with a 
syringe. The tubing was then placed into the tubing prep station and let sit until gold particles started to 
settle. Ethanol in the supernatant was carefully removed with the syringe and the tubing then rotated 
once by 180°. Afterwards, gold particles were evenly distributed on the inner side of the tube by 




tubing, corresponding to ~2 µg DNA per cartridge. For quality control, gold particles from individual 
bullets were eluted by rinsing in DNA loading buffer and subjected to gel electrophoresis (Fig. 13). For 
immunisation, cartridges were placed into the Gene Gun device and the pistol connected to a helium 
bottle with a pressure gauge. Delivery of the DNA/Gold particles into skin was achieved by shooting 
three times onto the shaved abdomen of the animal with a pressure of 350 psi. 
 
 
Fig 14. Quality control of Gene Gun ammunition. To verify equal loading onto the cartridges, DNA integrity and to estimate the DNA amount 
transferred by each shot, original plasmid DNA (1.5 µg, lane DNA) or DNA eluted from two randomly selected bullets (B1, B2) were analysed 
by agarose gel electrophoresis after (+) or without (-) EcoRI control restriction digestion. Representative results of cartridges from the DNA 
prime/SVP boost immunisation study with FFV Env or Env MPER hybrid antigens are shown. All plasmids show an 658 bp insert after EcoRI 
digestion as expected (black arrow) and are loaded with equal amounts of DNA ( ~1.5 µg DNA/bullet). 
 
 
2.6.2 Bleeding and serum preparation 
Animals were bled at suitable time points after immunisation by retrobulbar bleeding under anaesthesia. 
The collected blood samples were incubated for 2 h at room temperature before they were swirled gently 
with a glass rod to activate the coagulation cascade. Samples were incubated overnight at 4°C to allow 
clogging to complete. Then, the coagulum was sedimented by centrifugation (3.000 g, 10 min, 4°C) and 
the serum supernatant recovered in fresh tubes. To remove any potential contamination with 
erythrocytes, the crude serum was subjected to another centrifugation step (10.000 g, 4 min, 4°C) and 
again transferred into a new tube. Finally, all sera were decomplemented in a water bath at 56°C for 30 







3.1 HIV-1 epitope delivery using the foamy viral TM protein 
In order to use the TM protein of FV as epitope scaffold, knowledge about immunogenic regions in that 
protein was essential to assure effective immune responses to HIV-1 epitopes in the later hybrid 
antigens. In the beginning of this project, no information about the immunogenicity of the TM proteins 
of FV was available and in contrast to previous studies with gammaretroviral TM proteins, no clear 
sequence homology between the FV gp48 and the HIV-1 gp41 MPER was evident to allow a conclusive 
epitope exchange. Thus, a basic question to be answered was if the TM protein of FV is an immunologic 
target during FV infection and which epitopes were recognised by such potential antibodies. Next to 
this, it should be investigated which immune responses can be induced when recombinant TM protein 
is used for immunisation, as this would facilitate later optimisation of epitope insertion and provide 
control sera for establishment of any TM protein-related assays.  
 
3.1.1 Construction of FFV and PFV TM expression plasmids 
For recombinant production of the FFV and PFV TM proteins, constructs suitable for eukaryotic as well 
as prokaryotic expression were produced. By cloning the TM target sequence into a retroviral backbone 
for eukaryotic expression it was sought to overcome low protein yields associated with cell line 
production by the option to generate stable clones. However, although sequence integrity was confirmed 
in these constructs, no distinct overexpression was evident upon transfection into 293T cells by Western 
blotting (not shown). In contrast, expression from the prokaryotic expression constructs was easily 
detectable using the same method. As milligram amounts were needed for the intended immunisation 
studies, further efforts were focused on production of the TM protein in E. coli. A set of expression 
plasmids were cloned, in which the sequence of the full length FFV and PFV TM protein or the 
ectodomain, lacking the fusion peptide and membrane spanning domain, was fused to a N- or C-terminal 
affinity tag. Most of the constructs were rejected from further experimentation as either neglectable 
expression was observed, protein instability was evident (N-terminal His-tag fusions) or insolubility 




proteins). In case of the FFV TM protein, a codon-optimised ectodomain sequence (kindly provided by 
Prof. Löchelt, DKFZ) was finally cloned as it gave about five-fold increased expression compared to 
the wild type sequence. From the various constructs tested, GST-tagged TM proteins showed best 
expression and including a C-terminal His-tag permitted purification of full-length proteins. Therefore, 
double-tagged versions of the FFV and PFV TM ectodomains (Fig. 15) were selected for the 
establishment of suitable expression and purification protocols. 
 
 
Fig. 15 Structural features of the FV envelope proteins and presentation of resulting recombinant proteins. ELP - envelope leader peptide, 
SU - surface envelope protein, FP - fusion peptide, TM - transmembrane envelope protein, MSD - membrane spanning domain. Black arrows 
indicate furin cleavage sites. Amino acid numbering is corresponding to Uniprot entry O56861 for FFV and P14351 for PFV, respectively. The 
theoretical molecular weights or the recombinant GST-fusions are indicated on the right. Figure adopted from Mühle et al., 2012. 
 
 
3.1.2 Expression optimisation using a 96 deep well screening assay 
Despite being detectable by Western blot, low levels of protein were obtained upon overexpression in 
the initial BL21 bacterial host under standard expression conditions (LB medium, 37°C, 1 mM IPTG) 
on the Coomassie level. To overcome this, a 96 deep-well assay was developed for identification of 
suitable expression conditions by simultaneously testing the most important factors influencing 
expression, including bacterial strains, media, transformants, IPTG concentrations and temperatures in 
parallel to the empty, GST-expressing vector as control. For screening, the cloned expression plasmids 
were transformed into specialised E. coli expression strains with differences in their genetic background 
that could provide benefits for TM protein expression. Shuffle T7 Express cells allow the formation of 
disulphide bonds in the cytosol of E. coli through overexpression of the cytoplasmic disulphide 
isomerase DsbC (228, 229), C43 cells contain an uncharacterised mutation compensating for expression 
of toxic and particular membrane proteins (230, 231) and the SCS-1/pSE111 cells are K12 derivatives 
containing the pSE111 plasmid supplying arginine t-RNAs for improved expression of eukaryotic 




but has the genetic background of the BL21 strain (232). As shown below, remarkable differences in 
production levels were found dependent on the conditions applied (Fig. 16). The PFV TM protein was 
effectively produced in three of four of the selected bacteria with no major influence of the various 
media or IPTG concentrations. The FFV TM protein was also expressed in three out of four, yet three 
different bacteria strains and was exclusively detectable in the presence of TB medium, indicating a 
favourable role of glycerol as carbon source. The results of the screening demonstrated the usefulness 
of small-scale optimisation and greatly facilitated the subsequent purification process. 
 
Fig. 16 Influence of the expression conditions on protein production. Bacterial strains Shuffle T7, C43, SCS-1, and Rosetta 2 were 
transformed with the expression constructs of the TM proteins of FFV and PFV and two transformants (TM1, TM2) along with the empty 
expression vector (KG) were grown in different media (LB, 2YT, TB). Expression was induced with increasing concentrations of IPTG (grey 
arrows, corresponding to 0, 0.1 and 1 mM IPTG). Recombinant TM proteins and GST from the parental vector are indicated by black arrows. 





3.1.3 Purification, refolding and characterisation of the produced TM proteins  
As a first step to establish a purification protocol for FFV and PFV TM, solubility of the fusion proteins 
was tested. Both antigens were found in the insoluble fraction, even when fused to the solubility 
enhancing MBP or GST proteins or when mild non-ionic detergents were used for extraction (data not 
shown). In consequence, purification was performed under denaturing conditions by including 6 M 
GuHCl or 8 M Urea in the wash- and elution buffers, respectively. Subsequent dialysis of purified 
antigens against phosphate buffers resulted in protein precipitation, therefore, the denaturant was 
removed by a step gradient during Ni-NTA affinity chromatography with elution in PBS buffer 
containing imidazole (221). Although only low yields of soluble protein was obtained by this way (~0.5 
mg/L expression culture), this was sufficient for setting up a FFV TM protein-based ELISA as described 
below. Alternately, a sarkosyl-based purification protocol was later found to be more practical as no 
differences in ELISA sensitivity was observed but protein yields increased to 16 to 18 mg/L expression 
culture for PFV and FFV TM, respectively. In this protocol the inclusion bodies were solubilised by the 
ionic detergent sarkosyl at high concentrations and then diluted below its critical micelle concentration 
to allow refolding before purification on Ni-NTA columns. As interference of the 26 kDa GST fusion 
partner onto the structure or immunogenicity of the antigen might be expected, purified proteins were 
also treated with thrombin to remove the GST moiety. Analysis of all four proteins by SDS-PAGE, gel 
filtration and CD spectroscopy showed that they were sufficiently pure, mainly monomeric and with 
defined secondary structure (Fig. 17). Attempts to crystallise the proteins are currently ongoing in the 







Fig. 17 Purification and characterisation of produced FFV and PFV TM proteins. (A) SDS-PAGE of lysates from non-induced (L) and IPTG-
induced (IL) bacteria  transformed with FFV TM and PFV TM expression plasmids before (-) and after (+) expression optimisation and proteins 
after purification. M, Marker; E, Elution fraction after affinity chromatography and gel filtration; ET, TM proteins after removal of the GST 
residue through thrombin digestion. (B) Gel filtration of purified proteins with (insets) or without thrombin treatment (large chromatograms) 
reveals that there are mainly monomeric. V0, dead-volume of the column. Ovalbumin (43 kDa) was used for calibration (C) CD-spectroscopy 
of purified FFV and PFV TM proteins with (dashed line) and without (solid line) the GST fusion partner. Chromatograms show that all proteins 
have defined secondary structure with typical plateaus at 208 and 222 nm corresponding to a dominant alpha helical content. Figure adopted 










3.1.4 Immunisation studies with FV TM proteins and characterisation of the antisera 
To study the humoral responses in animals and to produce TM-specific antisera, the purified 
recombinant FFV and PFV TM proteins were used to immunise rats and in case of the FFV TM protein 
also one goat. High levels of binding antibodies were induced in all animals when the sera were titrated 
against the respective TM antigen (Fig. 18). Analysing the FFV TM sera by epitope mapping using 
overlapping peptides showed that responses were directed against the FPPR region and the central part, 
however, no antibodies against the MPER domain were generated. Although high levels of TM-specific 
antibodies were present, the antisera did not prevent FFV or PFV infection in an indicator cell line or 
qRT-PCR-based neutralisation assay, even if low serum dilutions (1:10) were used (data not shown). 
 
Fig. 18 Characterisation of antibody responses after immunisation with purified TM proteins. (A) Antibody titres after the indicated number 
of  immunisations with FFV TM (goat 348, rats 321), GST-free FFV TM (rats 340) or PFV TM protein (rats 343). Antisera from all animals were 
titrated in an ELISA using 200 ng recombinant TM proteins as antigen. PI, pre-immune serum. (B) Representative epitope mapping of the 
antiserum from goat 348 using PepSpot membranes spotted with overlapping peptides of the FFV TM ectodomain (dilution 1:800). 
Recognised peptides are listed and derived epitopes framed in black. (C) Summary of epitopes recognised in immunised animals. The amino 





3.1.5 Use of the FFV TM protein for serological screening of FFV infection  
Through collaboration with the LABOKLIN GmbH, more than 400 cat sera were available to test them 
for their potential reactivity against the FFV TM protein in a newly established ELISA. From these 
samples, 262 sera were analysed in parallel with established FFV Gag and Bet ELISAs in the laboratory 
of Prof. Löchelt to validate the TM ELISA results. Using the purified FFV TM antigen coated to ELISA 
plates, clear reactivity in a subset of the sera was detectable, which was confirmed to be TM-specific by 
immunoblotting (Fig. 19). Importantly these reactivity correlated well with that observed by ELISA 
screening using the FFV Gag antigen and reached higher sensitivity compared to the Bet ELISA, 
suggesting that the FFV TM protein-based assay is an interesting alternative for detection of FFV 
infection. By screening all sera in the panel, for the first time the prevalence of FFV infection in 
Germany was determined to be 39%. By analysing the data in regard to animal characteristics, a clear 
correlation between age and infection status was found with a significant increase of FFV infection after 
the first year of birth. Furthermore, the castration status positively influenced the FFV infection rate, but 
gender-related differences were not observed (Fig. 20).  
 
 
Fig. 19. Serological screening for FFV infection using recombinant FFV TM, Gag and Bet proteins. Purified TM protein (200ng/well) was coated 
on ELISA plates and incubated either with antiserum of goat 348 (pos) and pre-immune serum (neg) or sera from cats with unknown FFV infection 
status. Clear reactivity of a subset of sera was evident (upper panel) and reactivity confirmed by FFV TM immunoblot (middle panel). By testing 
the same sera with established Gag and Bet ELISA (lower panel) a strong correlation between all three assays was found (red arrows). Figure 






Fig. 20. Prevalence of FFV antibodies in dependence on animal characteristics. Animals were stratified by age, sex, castration status (A, B, 
C, respectively) and the percentage of the sera positive in a TM protein-based ELISA, the total number of investigated animals and the p-
values (Students T-test) are given. Figure taken from Mühle et al., 2011. 
 
3.1.6 Identification of neutralising antisera and epitope mapping of FFV infected cats 
After demonstrating that TM-directed antibodies were generated during natural FFV infection, the 
strength of the TM response and the epitope specificity of these antibodies was analysed. Furthermore, 
as the TM proteins of retroviruses are often the target of nAb, it was of interest to examine whether a 
correlation between TM responses and neutralising activity is present. FFV positive sera were therefore 
titrated against TM protein by ELISA and tested in PCR and FeFAB indicator cell line-based 
neutralisation assays using the FFV-FUV-7 isolate. For initial screening, serum pools consisting of three 
sera per pool were studied. In the set of 30 pools, 15 were able to reduce infection to more than 95% at 
serum dilutions of 1:50 (Fig. 21 A). Assaying these sera individually, 13 sera were found to neutralise 




about 15% of the infected animals (Fig. 21 B and C). In comparison to the overall TM reactivity 
measured by titration against recombinant TM protein (average titre of binding antibodies ~1:1000, not 
shown), no clear correlation between the amount of binding and neutralising antibodies was evident. 
However, these results demonstrated that the TM protein is an important immunological target during 
natural FFV infection and rationalised its use as epitope scaffold. 
 
Fig. 21. Identification of FFV neutralising antibodies in sera of naturally infected cats. (A) Serum pools of FFV positive animals were tested in a 
qRT-PCR based neutralisation assay on CRFK cells at serum dilutions of 1:10 and 1:50 or in absence of serum (infection control). Neutralisation 
is expressed as reduction of proviral genomic DNA in infected cells, which was quantified with a FFV plasmid standard. (B) Individual analysis 
of neutralising serum pools identified in (A) in a FeFAB indicator cell based NT-assay at indicated serum dilutions. Several sera show clear 
reduction of infection even at serum dilutions of 1:400. (C) Determination of the specificity of FFV neutralisation by an HIV-1 NT-assay using 
TZM-bl indicator cells and titrated pNL-4.3 supernatants. Monoclonal antibody 2F5 was used as positive control at concentrations of 10, 5, 2.5 





Eight of the identified FFV positive sera containing strongly and weakly neutralising antibodies were 
subjected to epitope mapping on Pepspot membranes as used before for immunised animals. In contrast 
to the pattern seen before, the antibody responses in the naturally infected cats localised to the FPPR 
and MPER domain but not to the glycosylated central part of the TM protein (Fig. 22). Interestingly, 
some of the antisera showed a bipartite recognition of the MPER domain, reminiscent to what has been 
found for TM-directed antibodies in case of HIV-1 and gammaretroviruses. However, although MPER 
antibodies were detectable in all of the naturally infected cats, again no obvious correlation with 
neutralising capacity of the sera was apparent. For better visualisation, a schematic overview comparing 
the epitopes of immunised an naturally infected animals is given in Figure 22 B.  
 
 
Fig. 22. Epitope mapping of antisera from naturally FFV infected cats. (A) Epitopes recognised by naturally FFV infected cat sera as determined 
with overlapping peptides from the FFV TM ectodomain. The spotted amino acid sequence is given in single letter code and identified epitopes 
indicated by grey bars (B) Schematic presentation of the TM protein of FFV showing the location of the fusion peptide (FP), the fusion peptide 
proximal region (FPPR), the membrane proximal external region (MPER) and the membrane spanning domain (MSD). The location of the 
predicted glycosylation sites (Y) and the cysteine residues (C) is indicated. For comparison, the localization of the epitopes recognised by the 





3.1.7 Exchange of immunogenic epitopes in FFV Env by HIV-1 FPPR and MPER domains 
The data presented above indicated that although not clearly linked to neutralisation, the FPPR and 
MPER domain were immunogenic during natural FFV infection and therefore suitable for insertion of 
the intended HIV-1 epitopes. Furthermore, as the immunogenic regions in the FFV MPER were located 
close to the transmembrane domain as the epitopes of 2F5 and 4E10 in gp41, the introduction close to a 
lipid environment could provide a potential benefit for the induction of nAb. Based on the epitope 
mapping data, immunogenic consensus sequences in the FPPR and MPER of the FFV TM protein were 
defined. Since the overall identity to the corresponding HIV-1 sequences on the amino acid level was 
low, additional bioinformatic parameters including secondary structure, hydrophobicity, surface 
exposure and spacing to neighbouring functional domains (fusion peptide, membrane spanning domain) 
were also considered to select insert positions (data not shown). Next, to further increase the probability 
of finding a position in which the overall protein integrity remains uncompromised, the domains were 
shifted by three amino acids to the C- or N-terminus, representing a ¾ turn in the alpha helical domains. 
Overall, six HIV-1 FPPR hybrids and two MPER chimeras were designed and in parallel, the 
corresponding FPPR and MPER domains from PFV were included as controls (Fig. 23). The respective 
domains were cloned into an optimised full-length Env expression construct (pBC-EnvG2) by Anne  
 
Fig  23. Generation of chimeric FFV Env proteins containing HIV-1 FPPR and MPER epitopes. (A) Insertion of HIV-1 FPPR (red) or PFV FPPR residues 
(dark red) into selected positions of the wildtype FPPR region of the FFV TM protein. The furin cleavage site (scissors), the fusion peptide 
(underlined) and the immunogenic domain obtained by epitope mapping of naturally infected cats (bold) are indicated. (B) Insertion of HIV-1 
MPER (blue) or PFV MPER residues (dark blue) into the MPER region of the FFV TM protein. The wildtype sequence with immunogenic epitopes 
derived from epitope mapping (bold) and residues of the membrane spanning domain (underlined) are shown. Residues underlined in the HIV-






Bleiholder  (DKFZ, Heidelberg). Compared to wildtype Env, the active splice donor and acceptor pair 
naturally flanking the membrane spanning domain of FFV Env was silently mutated in this construct to 
prevent the formation of env transcripts that lack the transmembrane domain. Therefore, they are more 
efficiently anchored into the plasma/viral membrane instead of being secreted as soluble Env protein 
only (A. Bleiholder, unpublished). When the constructed Env chimeras were transfected into 293T cells 
and analysed by immunoblots using the TM-specific goat serum 348, those having the PFV FPPR or 
MPER domain as well as hybrids containing the HIV-1 MPER were efficiently expressed and processed 
by cellular proteases. In contrast, insertion of HIV-1 FPPR sequences resulted in complete loss of furin 
cleavage and occurrence of the Env precursor protein only (Fig. 24). Interestingly, all of the constructs 
that were found to be cleaved, could be detected in concentrated cell culture supernatants, indicating 
that FFV Envs are able to bud in absence of Gag as subviral particles (SVPs) as has been described for 
PFV Env and was further confirmed for the FFV Env shown here by density gradient ultracentrifugation 
(A. Bleiholder, unpublished). Further investigations on the FFV/HIV-1 MPER hybrids showed that their 
sub-cellular localisation as well as their glycosylation pattern was similar to wt Env and that both 
chimeric proteins were effectively immunoprecipitated by 2F5 and 4E10, suggesting that the HIV-1 
MPER epitopes were accessible under non-denaturing conditions (A. Bleiholder, unpublished). 
However, in contrast to the PFV chimeras, both HIV-1 MPER Envs did not allow marker gene transfer 
when used in pseudotyping experiments with Env deficient FFV (Fig. 24), proposing an inability of the 
hybrids to permit fusion of virus particles with the cellular plasma membrane. In consequence, this 
strategy could not be used to construct replication-competent vectors, however, further efforts were 
undertaken to examine the usability of the secreted MPER containing SVPs as antigens for induction of 





Fig 24. Characterisation of chimeric FFV Env proteins containing HIV-1 FPPR and MPER epitopes. (A) Expression and processing of wildtype FFV 
Env (pCF-7, EnvG2) and when modified to contain the HIV-1 or PFV FPPR (left) or HIV-1 and PFV MPER (right). 293T cells were transfected with 
corresponding expression constructs or empty vector (pCDNA) and analysed 2 days post transfection. Clone numbers correspond to the various 
positions in which the chimeric sequences were introduced. A and B are two individual clones with the same insert. Size of marker proteins, 
the gp130 Env precursor, the cell lysate associated form of TM (TMCL) and the mature gp48 TM protein are indicated by arrows. Whereas 
modification of FFV FPPR residues was compatible with Env processing only in case of FFV/PFV chimeras, constructs containing HIV-1 and PFV 
MPER sequences were both efficiently cleaved. (B) Analysis of secretion of wildtype and chimeric Envs. Supernatants from transfected 293T 
cells were concentrated by ultracentrifugation and analysed by immunoblot with TM specific goat serum. Envs found to be efficiently cleaved 
were secreted into the supernatant. (C) Marker-gene transfer (focus forming units, FFU) of supernatants obtained through parallel transfection 
of Env-deficient, beta-gal expressing UbiLacZ FFV vectors with wildtype (EnvG2) or chimeric Envs containing the HIV MPER, PFV MPER or both 
PFV FPPR and MPER, respectively. Whereas PFV hybrids produced infectious virus able to infect new cells, no marker gene transfer was 
observed by pseudotyping the vector with Envs containing the HIV-1 MPER. Data kindly provided by A. Bleiholder (unpublished). 
 
 
3.1.9 Immunisation studies using chimeric FFV/HIV MPER SVPs 
For evaluation of the immunogenicity of the described SVPs in immunisation experiments, large scale 
expression in cell stacks and purification protocols using cross-flow filtration concentrated supernatants 




(A. Bleiholder, unpublished). The purified particles were reasonable pure and contained the TM protein 
as judged by silver staining. However, BSA as a main contaminant could not be separated by the 
purification protocol applied and overall yields of purified SVPs, in particular that of both HIV MPER 
hybrids which were less efficiently secreted into the supernatant, were relatively low (Fig. 25).  
 
 
Fig 25. Purification of FFV subviral particles and amounts obtained after large-scale production. (A) Purity of SVPs used for immunisation 
of rats. 5 µl of SVPs from wildtype FFV Env (EnvG2) or Envs containing the HIV-1 MPER domains (MPER1, MPER2) from two different 
purification charges (I, II) were subjected to SDS-PAGE and silver staining. Right lane: Immunoblot of EnvG2 SVPs detected with the TM-
specific goat serum 348. The glycosylated gp48TM protein is visible as fuzzy band below the BSA contaminant (arrows). Molecular weight 
marker is indicated on the left. (B) Yields of indicated SVPs in individual charges after large-scale production. The amount of TM protein in 
SVP preps was estimated by parallel loading of serial dilutions of recombinant FFV-TM protein during immunoblot. Data were kindly provided 
by Anne Bleiholder (DKFZ, Heidelberg). 
 
To enhance immune responses, a DNA prime, SVP boost protocol was chosen for immunisation 
experiments in rats.  Four animals per group were immunised twice by gene gun bombardment with 
plasmids pBC-EnvG2 (group 376), pBC-MPER1 (group 377) or pBC-MPER2 (group 378) in a three 
weeks interval, followed by injection of SVPs pooled from both purification charges three weeks later. 
In case of rats 377 and 378, further boosting was performed using 250 µg of an recombinant FPPR-
MPER antigen (F2-M2, see section 3.3) to enhance HIV-1 MPER directed responses. Subsequently, 
antisera were titrated in ELISAs against recombinant FFV TM protein to analyse overall immune 
responses as well as recombinant gp41 purified from bacteria and a synthetic HIV MPER peptide. As 
shown below,  the antibody response induced against the FFV TM protein at serum dilutions of 1:500 
was moderate in group 376 which obtained EnvG2 DNA and SVPs and weak in groups immunised with 
the MPER chimeras until further boosting with recombinant FPPR-MPER antigen (4th injection, Fig. 




showed as expected no reactivity against these antigens. However, a similar pattern was observed in 
groups 377 and 378 obtaining the MPER antigens until the 3rd immunisation (2x DNA, 1x SVP boost). 
A more robust response against gp41 and MPER peptide was obtained after boosting with the 
recombinant FPPR-MPER antigen with no differences between groups 377 and 378. Analysing the 
antisera for neutralising activity, no reduction in the level of HIV-1 infection was observed (not shown).  
 
 
Fig 26. Immunisation studies in rats using FFV Env DNA and SVPs as antigen. (A) Immunisation schedules for rat groups 376,  377 and 378. 
Rats were immunised twice by Gene Gun immunisation (DNA) with indicated expression plasmids (EnvG2, MPER1, MPER2) followed by 
boosting with subviral particles (SVP) expressed and purified from 293T cells transfected with the same plasmids. In case of group 377 and 
378, further boosting of HIV-1 specific responses was achieved by injection of the recombinant FPPR/MPER antigen F2-M2. PI, 1st, 2nd 3rd and 
4th correspond to pre-immune serum or the number of immunisations and bleedings as indicated. (B) Analysis of rat antisera by ELISA at 
serum dilutions of 1:500, using recombinant FFV GST-TM protein (TM), gp41 or a synthetic MPER peptide (MPER) as antigen. The number of 
immunisations and reactivity for individual animals 1-4 (coloured bars) is indicated. No antiserum was available in cases where no bars are 





3.2 HIV-1 epitope delivery by FFV Bet fusion proteins 
In a second approach aiming to construct replication-competent FV vectors expressing HIV-1 epitopes, 
the accessory Bet protein of FFV was used as fusion partner. As mentioned earlier, Bet has been 
described to be immunogenic during FV infection and fusion of a neutralising epitope of feline 
calicivirus (FCV) to Bet was successfully used to induce partial protection against high-dose FCV 
challenge in cats (118). In order to characterise epitope accessibility and immunogenicity of the small 
HIV-1 epitopes when expressed in the Bet context, they were first produced as recombinant proteins 
and thoroughly analysed. Subsequently, the strategy was transferred into the FFV context.  
 
3.2.1 Design and construction of Bet and Bet/HIV-1 expression plasmids 
The basis for production of FFV Bet and Bet/HIV-1 hybrid proteins (Fig. 27) were expression plasmids 
constructed stepwise by subcloning of the full-length Bet sequence from plasmid pBC12-Bet (kindly 
provided by M. Löchelt, DKFZ) into the prokaryotic pQE-30 Xa expression vector, followed by the 
introduction of the intended HIV-1 epitopes. In cloning step one, four additional amino acids (AGAA)  
 
 
Fig. 27. Schematic presentation of gp41 of HIV-1 (A) and of FFV Bet and the FFV Bet/HIV-1 fusion proteins (B). FP fusion peptide, FPPR 
fusion peptide proximal region, NHR/CHR N-terminal and C-terminal helical region, MPER membrane proximal external region, MSD 
membrane spanning domain, C-C cysteine loop, TM transmembrane envelope protein, His histidine tag, Factor Xa factor Xa protease cleavage 
site, Bet full-length FFV Bet sequence, Linker 4 (FFV Bet) or 15 (all other constructs) amino acid spacer. E1–HIV-1 FPPR-derived domain, E2–
HIV-1 MPER-derived domain, E1–E2, HIV-1 E1 and E2 domains connected by a flexible loop sequence. The theoretical molecular mass of all 
antigens is indicated. Lines below the E2 sequence of gp41 of HIV-1 mark the location of the neutralising epitopes of 2F5 and 4E10. Figure 




encoding a NaeI site were introduced just before the Bet stop codon which allowed the subsequent 
insertion of HIV-1 FPPR and MPER sequences with extra spacer residues (SGSAGAGAGGG), 
included to spatially separate HIV-1 epitopes from Bet. Additionally, the  construct Bet-E1-E2 was 
designed in which the FPPR and MPER domain was connected through a loop element in order to 
potentially stabilise interactions that promote enhanced MPER antibody binding (Fig. 28). This 
construct was based on the de novo designed alpha-turn-alpha (αtα) peptide (46, 233), in which the N- 
and C-terminal helices were replaced by HIV-1 FPPR and MPER residues with an amino acid spacing 
that allows contact of critical residues as found in the crystal structure of gp41 (81). As the loop element 
and eight flanking amino acids of the N- and C-terminal alpha helical residues were left unaltered, these  
 
 
Fig. 28.  Design and bioinformatic characterisation of the E1-E2 antigen.  (A) Amino acid sequence of E1-E2 and individual domains. The fusion 
peptide proximal region (FPPR, red), the membrane proximal external region (MPER, blue), the alpha helical flanking regions (α, black) and the 
β-turn loop element (L, green) are highlighted in colour. (B) Chou-Fasman secondary structure predictions for the E1-E2 antigen, plotting the 
probability score to form alpha helices (left diagram) or beta-turns (right diagram) against individual amino acids. Note the distinct structural 
break at amino acids 30-34, representing the loop element. Graphs were obtained with the ProtScale software provided on the expasy 
proteomics server (http://web.expasy.org/protscale). (C) Model of E1-E2 interaction and positioning of FPPR and MPER contacting amino acids. 
The 15 amino acid linker and the Bet fusion partner are schematically shown (D) Alpha helical wheel projections of both domains with the 
positioning of critical residues as in (B) indicated by red circles. Projections were made with the help of the Wheel program provided by Don 




construct should promote interactions of the FPPR and MPER as found in the wildtype αtα peptide. 
Indeed, bioinformatic analysis confirmed the proposed secondary structure and correct positioning of 
FPPR and MPER residues. Having constructed the described plasmids, suitable expression and 
purification methods had to be established in a next step. The Bet protein constituted the major part of 
the fusion proteins and the corresponding expression plasmid was available first. Therefore, protocols 
were established for Bet and then finally applied also to the hybrid proteins. 
 
3.2.2 Production of FFV Bet and protein characterisation 
As a first step, expression screening in deep well plates was performed as described before for the FFV 
and PFV TM proteins. SCS-1 bacteria and to a lesser extent T7-Shuffle allowed production of the protein 
at high levels in total lysates (Fig. 29A). Unfortunately, only low amounts of recombinant protein were 
found in the soluble fraction, which were slightly increased at reduced expression temperatures but did 
not exceed the Western blot level (Fig 29B). Since the HIV-1 part of the Bet-E1-E2 protein was designed 
to form a conformational epitope, it was essential that the intended proteins were available in a soluble 
form to allow formation of such structures. Various attempts were undertaken to achieve soluble 
expression of Bet, including fusion to GST, MBP and Thioredoxin as solubility-enhancing fusion 
proteins, use of additional specialised bacteria for expression, supplementation of growth media with 
Zn2+ and DTT or performing expression under a more broad temperature and IPTG profile as in the 
initial screening (data not shown). None of this factors did improve yields of soluble Bet, pointing to an 
inability of E. coli to manage production of a correctly folded protein, probably due to the large number 
of 13 cysteines that may contribute to structure stabilisation in native Bet. As a consequence, purification 
under denaturing conditions using the His-tag was performed (typical yields 35 mg/L) and further efforts 





Fig. 29. Expression optimisation for FFV Bet. (A) SDS-PAGE analysis of protein production in total lysates with expression strains SCS-1, T7-
Shuffle, C43 and Rosetta 2 bacteria at 30°C expression temperature. The type of medium (LB, 2YT, TB, SOC), the amount of IPTG (c= 0 mM, 
grey arrows 0.1 and 0.5 mM), Lysozyme used for lysis and the expected size of recombinant FFV Bet is indicated. SCS-1 and to a lower extent 
T7-Shuffle promote expression (black circles). (B) Expression of FFV Bet in the soluble fraction. Labelling of gels is as in (A) but include results 
obtained at 20°C (lower panel) and an anti-His blot for detection of low levels of proteins (grey boxes). Whereas lowering the expressing 
temperature had an positive effect of protein solubility, yields did not exceed the Western blot level. 
 
A refolding screening assay based on 96-well plates was developed to address this issue. Denatured and 
reduced protein from the Ni-NTA purification step was diluted into Tris buffers with or without co-
solvents that aid refolding processes by various mechanisms. Additionally, a redox-system based on 
different ratios of oxidised and reduced glutathione (GSSG/GSH) was included to allow formation of 
disulphide bridges that might be necessary to stabilise the soluble form of Bet. After renaturation for 
two days under the distinct conditions, the Bet protein was captured on 96-well Ni-NTA plates and 
functional refolding analysed by measuring binding of the Bet ligand feline APOBEC3Z2b, purified as 
soluble GST-fusion protein. From all conditions tested, the presence of L-Arginine had significant 






Fig. 30. Screening for suitable refolding conditions for FFV Bet. Denatured and reduced FFV Bet was renatured by rapid dilution into TrisCl-
based refolding buffers without or with additional folding enhancers (L-Arg, Glycerol, PEG, Sucrose, Sarcosyl). Buffers were  further supplied 
without or with a redox system based on oxidised and reduced glutathione (GSSG/GSH, see legend for colour code, the concentrations of 
red/ox glutathione is given in mM). After incubation at 4°C for 2 days and centrifugation, soluble proteins were captured on Ni-NTA plates 
and probed with 500 ng of purified of GST or feline APOBEC3Z2b (GST-feA3, inset). After washing, bound GST proteins were detected by an 
HRP-coupled anti-GST antibody and plates developed with a colorimetric OPD substrate. Refolding in the presence of L-Arg was most 
successful and the presence of a redox system was essential to obtain interaction. Excessive amounts of oxidised glutathione further 
improved refolding efficiency with ratios of 1/3 mM GSH/GSSG giving highest reactivity (black arrow). 
 
 
action of both proteins occurred, suggesting that formed disulphide bridges in Bet are essential to allow 
Bet/APOBEC3 engagement. Excessive amounts of GSSG thereby slightly improved binding activity, 
which might be explained by formation of a mixed disulphide intermediate with GSSG, which is then 
slowly replaced by GSH. Similar advantages have been seen during refolding of tissue plasminogen 
activator (t-PA) containing 17 cysteines and were attributed to a higher solubility of GSSG-coupled 
refolding intermediates. In respect to these data, large scale refolding of Bet was performed under the 
identified conditions, the protein was subsequently dialysed against phosphate buffer and concentrated 
by another Ni-NTA chromatography step using non-denaturing phosphate buffers supplied with 
imidazol. SDS-PAGE analysis and CD-spectroscopy demonstrated a sufficient purity of purified Bet 
and the presence of defined secondary structures, which were in good agreement with values predicted 






Fig. 31. Purity of FFV Bet and CD analysis of secondary structure in the refolded protein. (A) SDS-PAGE and Coomassie staining of purified 
FFV Bet. Molecular weights and the Bet protein at its expected size of 46 kDa (arrow) is indicated. The three lanes correspond to Elution 
fractions 1-3, respectively. (B) CD spectroscopy of renatured FFV Bet measured in a Jasco720 spectropolarimeter. The pattern resembles a 
typical chromatogram of a mixed alpha-beta protein and measured values correlate well with the secondary structure content predicted 
from the primary sequence (predicted/measured inset). 
 
3.2.3 Production and characterisation of Bet/HIV-1 hybrid proteins 
The protocols established for FFV Bet were successfully transferred to the Bet/HIV-1 hybrid proteins 
described earlier and all proteins could be obtained at high purity with yields of 11-18 mg/L expression 
culture. A first characterisation of these proteins by Western blot using 2F5 and 4E10 as well as a FPPR 
directed antiserum (J. Kreuzberger, unpublished), demonstrated their specific recognition by respective 




Fig 32. Characterisation of FFV Bet and Bet/HIV-1 fusion proteins. (A) Purity of the produced antigens. Two micrograms of recombinant 
proteins was loaded for SDS–PAGE and stained by Coomassie blue. The molecular mass of the marker is indicated. (B) Recognition of the 
produced antigens by the monoclonal antibodies 2F5 and 4E10 and a FPPR-specific antiserum. One hundred and fifty nanograms of 
recombinant proteins were transferred onto a PVDF membrane and tested with the antibodies 2F5 (0.4 µg/ml), 4E10 (1.2 µg/ml) and an E1-





To investigate binding of 2F5 and 4E10 also under non-denaturing conditions, antigens were coated on 
ELISA plates overnight at 4°C and then probed with both antibodies in serial dilutions. In case of 2F5, 
no significant differences in recognition of the only MPER containing antigen Bet-E2 was observed 
when compared to proteins that presented MPER and FPPR together, either through mixing (Bet-
E1+Bet-E2) or by direct linkage with a loop as in case of the Bet-E1-E2 antigen (Fig. 33). Interestingly, 
binding to the Bet-E1-E2 antigen was even slightly reduced when compared to Bet-E2 alone. However, 
in case of 4E10 a clear enhancement of recognition was obvious for the Bet-E1-E2 antigen, whereas the 
remaining antigens were detected weakly. These data showed that the HIV-1 epitopes are accessible for 
antibodies under physiological conditions and suggested that the FPPR domain contributed to improved 
binding of 4E10 but not 2F5 to the Bet-E1-E2 antigen. 
 
 
Fig. 33. Recognition of the produced antigens by the monoclonal antibodies 2F5 and 4E10 under non-denaturing conditions in an ELISA. 
One hundred nanograms of indicated Bet/HIV-1 antigens in phosphate buffer was coated and incubated with 2F5 (11.3 µg/µl) or 4E10 (11.9 
µg/µl) serially diluted as indicated, followed by detection with a HRP anti-human IgG antibody and OPD development. Whereas only minor 
differences in 2F5 binding were detected, threefold increased binding of 4E10 to the FPPR-stabilised Bet-E1-E2 protein was found. Figure 
taken from Mühle et al., 2013a. 
 
 
To study the binding of 2F5 and 4E10 to the hybrid proteins in more detail, SPR experiments were 
performed with both antibodies captured on Biacore-chips and antigens in solution (Table 11). High 
affinity binding of 2F5 in the nanomolar range was observed for all proteins containing the MPER 
epitope. In line with the previous ELISA results, the presence of FPPR residues did not allow increased 
affinity to the E2 domain and slightly reduced binding due to faster dissociation or slower association 




higher protein concentrations were necessary to measure interactions in case of the 4E10 antibody. Due 
to the precipitation of recombinant Bet/HIV-1 proteins above 1 mg/ml (15-20 µM), no suitable 
concentration ranges to obtain reliable data for the Bet-E2 antigen and the combination of Bet-E2 and 
Bet-E1 could be selected. At the highest concentration tested (8 µM), no binding of Bet-E1 and a weak 
signal (15 RU) for Bet-E2 were observed, suggesting that the KD values of Bet-E2 were probably in the 
micromolar range (data not shown). However, when the Bet-E1–E2 antigen was investigated, kinetic 
constants could be determined, as nanomolar protein concentrations yielded stable data. The dissociation 
constant of 223 nM resulted from slow target recognition (kon = 2.1 x 103/Ms) and a moderate 
dissociation rate (koff = 4.7 x 10-4/s). Thus, the SPR data substantiated the ELISA results and the 
beneficial effect of the FPPR residues for enhanced 4E10 antibody binding. 
 
TABLE 11. Kinetic constants determined by SPR measurements 
   
 
Analyt  Ligand kon [1/Ms] koff [1/s]   KD [nM]  
 
Bet-E1  2F5 -a -      - 
Bet-E2  2F5 2.0 x104 8.6 x10-5    4.3  
Bet-E1+Bet-E2 2F5 1.9 x104 1.1 x10-4    5.9  
Bet-E1-E2  2F5 1.1 x104 2.1 x10-4      19.0  
 
Bet-E1  4E10 - -      -  
Bet-E2  4E10 n.d.b n.d.    n.d.  
Bet-E1+Bet-E2 4E10 n.d. n.d.    n.d.  
Bet-E1-E2  4E10 2.1 x103 4.7 x10-4    223  
       
 
a no interaction observed 
b not determinable due to protein concentration limitations 
 
 
3.2.4 Immunisation studies with recombinant Bet/HIV-1 fusion proteins  
The results above showed that high affinity binding was achieved by fusing the HIV-1 epitopes to the 
C-terminus of Bet. To test if this translates into efficient immune responses to the HIV-1 parts in vivo 
and to determine the epitope specificity of such potential antibodies, all hybrid antigens were used for 
immunisation studies in rats. After three injections (250 µg/animal in CFA/IFA) in a three weeks 
interval, high levels of antigen-specific antibodies were induced in all animals, with titres reaching levels 
of 106-107 after the third immunisation when titrated against the administered antigen by ELISA (222). 
More importantly, antibodies to the respective HIV-1 parts were also elicited at high levels (titres of 




produced in bacteria were used as ELISA antigens (Fig. 34). Notably, the FPPR domain was more 
immunogenic than the MPER domain in all groups. The strongest MPER responses (titre of 8 x 103) 
was achieved when the Bet-E2 antigen was given alone or together with the Bet-E1 antigen (groups 365, 
366), whereas in group 375 (Bet-E1-E2 antigen) E2 reactivity was quite low. The gp41 response was 
similarly strong within all groups and confirmed to be specific by Western blot (222). These results 
demonstrated that Bet/HIV-1 hybrids can be successfully used to induce HIV-1 specific antibodies that 
recognise their corresponding epitopes also in the molecular context of gp41.  
 
 
Fig. 34. Reactivity of sera from animals immunised with Bet/HIV-1 proteins against recombinant gp41 and synthetic E1 and E2 peptides 
as measured in an ELISA. Sera were serially diluted in a range of 102–107. The endpoint titres of (A) sera from rat group 364, (B) sera from 
rat group 365 and (C), (D) sera from rat groups 366 and 375, all titrated against the E1 and/or E2 peptides as well as recombinant gp41, are 
given. The administered antigen is indicated in brackets. Figure reprinted from Mühle et al., 2013a. 
   
 
To further examine the epitope specificity of the induced HIV-1 antibodies, epitope mappings using 
microarrays spotted with overlapping peptides of the extended FPPR and MPER domains and two 
representative sera showing high overall antibody responses were performed (Fig. 35). In group 364 
which obtained the Bet-E1 antigen a clear response to the FPPR was observed, with the epitope 
TLTVQARQL being the only antigenic determinant. The HIV-1 specific antibody response in group 




as main epitopes, which overlapped with the residues targeted by 2F5 (underlined). Antisera which were 
immunised with the Bet-E1 and Bet-E2 mixture (group 366) showed a predominant response to the 
FPPR epitope TLTVQARQL and also recognition of MPER residues NEQELLELDKWASLW 
including the 2F5 epitope. The pattern observed in group 375 (Bet-E1-E2 antigen) was biased. Both sera 
reacted clearly with the FPPR epitope TLTVQARQL, but the E2 response was variable, with one serum 
recognising residues NEQELLELDKWA whereas no MPER response was found in case of the other. 
The epitope mapping data were consistent with the previous ELISA results and confirmed the overall 
lower E2 reactivity observed there. In terms of consistency and strength in which 2F5 epitope-specific 
antibodies were induced, the Bet-E2 antigen appeared to be superior to all other antigens.  
 
Fig 35. Epitope mapping of the sera from immunised animals. Microarrays spotted with overlapping 15-mer peptides of the prolonged HIV-1 
FPPR and MPER domains were incubated with antisera and bound antibodies detected by a fluorescent secondary anti-rat antibody. Results 
are plotted as relative light units (RLU) against the individual FPPR and MPER peptides. The group number, the administered antigen and the 
recognised epitopes as defined as central amino acids shared by overlapping peptides exceeding a 5000 RLU intensity threshold (grey line) are 






The previous analysis of antisera focused on short synthetic peptides of the FPPR and MPER domain 
and gp41 produced in bacteria. However, binding of the induced antibodies to native Env as presented 
on the virus surface or on infected cells would be essential to mediate virus neutralisation. To address 
this question, C8166 cells infected with HIV-1 and non-infected cells were examined by FACS and 
indirect immunofluorescence for antibody binding. Analysing the same sera as in the epitope mapping 
experiments together with a rat pre-immune serum as control, different degrees of binding to such cells 
were observed. Whereas the pre-immune serum did as expected show negligible staining, sera 
containing FPPR-directed antibodies bound weakly and sera containing MPER antibodies strongly to 
the infected cells (Fig. 36A). In immunofluorescence analysis, these sera showed signals with varying 
appearance. The representative serum from rat group 364, containing only FPPR-directed antibodies 
caused weak and diffuse staining with no clear pattern. Conversely, all antisera that contained MPER-
directed antibodies (rats groups 365, 366, 375) gave spot-like signals distributed on the surface of the  
 
 
Fig. 36. Binding of induced antisera to HIV-1 pNL-4.3-infected C8166 cells. (A) Analysis of antibody binding by flow cytometry 72 h after 
infection. Cells were probed with pre-immune rat serum (PI) or antisera from a representative animal from the rat group immunised with 
the antigen indicated above. (B) Indirect immunofluorescence of C8166 cells 48 h after infection. Fixed cells were transferred to slides where 
they were incubated with the same sera as in (A). Rat IgGs were detected by an Alexa-Fluor 488 antibody and analysed at a magnification of 
20x (upper panel) or 60x (lower panel). No reactivity was observed for the control (Ctrl), but antisera showed either diffuse staining when 
containing FPPR-targeting antibodies (rats 364) or distinct spots predominantly on the cell surface in antisera where MPER-directed 






cells (Fig. 36B). As the MPER epitope has been found to be highly accessible in the gp41 fusion 
intermediate state after attachment of gp120, these spots most probably represented antibodies binding 
to cell-produced or infecting virus. Despite the beneficial antibody properties found (high titre, binding 
to residues overlapping with the 2F5 epitope, binding to native Env), none of the sera did prevent HIV-
1 infection in a TZM-bl indicator cell line-based neutralisation assay at serum dilutions of 1:50 (222). 
 
3.3 Development of improved loop-stabilised HIV-1 FPPR/MPER antigens  
The data presented above demonstrated that during immunisation with the Bet/HIV-1 antigens mainly 
antibodies with specificity to the 2F5 epitope were induced whereas 4E10-like antibodies were absent 
in the sera. Since only the antigenicity of 4E10 was substantially improved in presence of the FPPR 
domain, any potential advantage achieved by the formation of the 4E10 FPPR/MPER conformational 
epitope did not translate into practice due to the low immunogenicity of the 4E10 epitope in the designed 
loop antigen. Further attempts were therefore undertaken to design proteins that allow improved 2F5 
binding to take advantage of the higher 2F5 epitope immunogenicity. The following sections describe 
experiments performed in this regard. 
 
3.3.1 FPPR/MPER antigen design and purification 
As mentioned earlier, the initial loop antigen used in the Bet-E1-E2 protein was derived from the αtα 
peptide modified to contain HIV-1 FPPR and MPER sequences. The lack of enhanced binding of 2F5 
to this initial antigen was probably a result of suboptimal spacing or residue contacts, which could arise 
from a divergence between the theoretical positioning of residues evaluated by bioinformatics and the 
finally obtained protein structure. In order to find a positioning in which formation of the affinity-
enhancing β-turn is possible, an extended set of antigens was designed in which the FPPR and MPER 
alpha helical flanking regions were stepwise shortened by single amino acid deletions (Fig. 37A). As 
both domains have mainly alpha helical character, these single amino acid deletions should result in 
shifting of both helices against each other, with an about 70° turn per deleted amino acid residue (Fig. 





Fig. 37. Recombinant antigen sequences and design. (A) Amino acid sequences of the nine recombinant helix-loop-helix antigens comprising 
the fusion peptide proximal region (FPPR), the membrane proximal external region (MPER) connected by a loop element (L) and the alpha 
helical flanking amino acids (α). The epitopes of the broadly neutralising antibodies 2F5 (ELDKWAS) and 4E10 (WFNITN) in the MPER are 
highlighted in bold. The antigens are named corresponding to the number of amino acid deletions introduced into the flanking regions of the 
FPPR (F0, F1, F2) or MPER (M0, M1, M2). (B) Alpha helical wheel projections of all antigens. Critical residues for 2F5 binding in the MPER (D 
and W residues of ELDKWA) and opposite residues in the FPPR are marked as red circles to visualise the influence of single amino acid 
deletions on the positioning of these selected amino acids. For purification, all antigens also contained a N-terminal His-tag after a Gly-Ala-




2F5 epitope may be presented at different faces of the antigen. Starting with the longest construct 
synthesised by GeneArt, deletions were achieved via PCR mutagenesis and the corresponding constructs 
named after the number of deletions introduced into the FPPR and MPER flanking regions (F0, F1, F2 
or M0, M1 and M2 respectively). The mutated sequences were then subcloned into pQE-30 Xa 
expression vector with an N-terminal His-tag for purification and spacer amino acids as in the original 
Bet-E1-E2 antigen (SGSAGAGAGGG). Expression optimisation was performed as described before, 
followed by large-scale expression in SCS-1 bacteria and TB medium. For purification, the sarcosyl 
extraction and refolding strategy established for the FV TM proteins was used, giving yields of about 3-
5 mg of protein per litre expression culture. On SDS-PAGE analysis, these proteins were highly pure 




peak in gel filtration analysis (Fig. 38C). Notably, all antigens appeared at a retention volume 
corresponding to an approximate molecular weight of 35 kDa (14 ml, Fig. 38C). This was about 
threefold the size that was expected for monomeric proteins (12 kDa, ~20 ml retention volume), 
indicating that the antigens spontaneously trimerised in solution. To further investigate the 
oligomerisation state, all antigens were subjected to native PAGE analysis. Here, the proteins appeared 
to varying degrees as monomers, dimers and trimers as apparent by their shifted migration pattern within 
the gel (Fig. 38B). Among the introduced deletions, those of the FPPR but not of the MPER flanking 
regions had the strongest impact on trimer stability. Whereas the F0 and F2 constructs were 
predominantly trimerised, the F1 deletion mutants were almost exclusively dimers (Fig. 38B). In a next 
step, the reactivity of the produced proteins with the monoclonal antibody 2F5 was tested in a non-
denaturing dot blot assay with serially diluted antigens or synthetic HIV-1 FPPR and MPER peptides 
(Fig. 38D). As in native PAGE experiments, shifting of the FPPR residues had the strongest impact on 
antibody binding and deletion of two FPPR flanking amino acids (F2 constructs) significantly enhanced 
the signal intensity for 2F5 but also 4E10 (Fig. 38D). To a lesser extent, rotating the MPER also 
improved recognition, particularly for the 4E10 antibody where a slight increase in binding with every 
additional MPER deletion was evident (Fig. 38D). Most importantly, the FPPR/MPER antigens were 
better recognised as the HIV-1 MPER E2 peptide spotted at equal amounts, again supporting the 
beneficial role of the FPPR residues for epitope stabilisation or orientation (lane E2, Fig. 38D). These 
results demonstrated that selective modification of the FPPR/MPER orientation influences the 
intermolecular interactions of the antigens, leading to an altered pattern of epitope accessibility for the 






Fig. 38. FPPR/MPER antigen purification and characterisation. (A) SDS-PAGE analysis of the recombinant proteins after Ni-NTA affinity 
purification. The arrow indicates the proteins at the expected molecular weight of ~12.5 kDa. (B) Native PAGE analysis of purified proteins 
reveals different tendencies to build monomers, dimers and trimers. Recombinant proteins (3 µg) were mixed with sample buffer without 
SDS or DTT and separated on native PAGE without boiling of the samples. Truncation of the FPPR flanking regions had the strongest impact 
on trimerisation, whereas the influence of MPER mutations is negligible. (C) Analytical gel filtration of purified proteins on a Superdex 75 
10/300 HR column with PBS, 0.1% sarcosyl at 0.4 ml/ min. Proteins elute as trimers in a main peak at 14 ml (T, ~35 kDa) next to some 
aggregated material (A, ~8 ml) and the monomeric form (M, ~20 ml). The column was calibrated with ovalbumin and lysozyme (45 kDa and 
17 kDa, not shown)  (D) Binding of the monoclonal antibodies 2F5 (0.3 µg/µl) and 4E10 (0.5 µg/µl) to serially diluted FPPR/MPER proteins or 
HIV-1 FPPR and MPER (E1, E2) peptides, each transferred to PVDF membranes by vacuum at indicated concentrations. Deletions in the FPPR 






3.3.2 Immune response to FPPR/MPER antigens in immunised mice 
To assess how far the observed differences in antigenicity relate to the immune response induced by 
these antigens, all FPPR/MPER proteins were used for immunisation experiments. The purified 
FPPR/MPER antigens were emulsified in incomplete Freund’s adjuvant and injected three times into 
BALB/c mice in a three weeks interval followed by final bleeding after additional two weeks (Fig. 39A). 
Except for the PBS control group and the pre-immune sera, in all sera from the final bleeding antibodies 
against gp41 were detected in Western blot analysis (Fig. 39B). Average antibody titres as determined 
by ELISAs using recombinant gp41 reached levels between 103 and 105. Sera from animals immunised 
with F2-M1 gave the highest response (Fig. 39C). Titres in a similar range were observed when synthetic 
HIV-1 FPPR and MPER peptides (E1 and E2) were used as antigen. However, dependent on the antigen 
injected, the strength of the response to either FPPR or the MPER differed (Fig. 39D). Upon rotation of 
FPPR residues, the E1 response increased steadily, with the most distinct pattern when two MPER 
flanking region deletions were present (Fig. 39D, upper panel). For E2 immunogenicity, both, rotating 
the FPPR as well as the MPER helix influenced the induced antibody pattern, with the strongest E2 
reactivity achieved with the construct F2-M1 (Fig. 39D, lower panel). Interestingly, only for the 
constructs able to stably trimerise in native PAGE (F0, F2, Fig. 38B) a strong impact of FPPR or MPER 
rotation on the antibody response could be detected, whereas the dimeric F1 constructs were basically 
unaffected (Fig. 39D). Taken together, these data showed that all antigens were immunogenic and that 
the differences in antigen properties also affected the resulting immune response. A positive correlation 
was found between the oligomerisation state and gp41 antibody titres. However, the increased 
antigenicity of the constructs for antibodies 2F5 and 4E10 predicted only in part the strength of the 
observed MPER immune responses in these experiments.  
 
3.3.3 Epitope specificity of induced antibodies 
Antisera of each group were pooled to fine-map the recognised epitopes using HIV-1 FPPR and MPER 
peptide microarrays (Fig. 40). Independent of the introduced deletions, one epitope, TLTVQARQL, was 
recognised in the FPPR by all antisera (Fig. 40, Table 12). Reactivity against the MPER peptides was 





Fig. 39. Immunisation and antibody response to FPPR/MPER proteins in vaccinated mice. (A) Immunisation schedule, adjuvant and route 
of administration for the conducted immunisation study in mice PI- pre-immune serum, IFA-incomplete Freund‘s adjuvant, s.c.- subcutaneous 
injection, i.m.- intramuscular injection. (B) Western blot analysis of antisera from individual mice (#1-5) after the final bleeding (dilution 
1:400) using purified gp41 as antigen. PI – pre-immune serum pool of the group indicated. (C,D) Titration of the antisera against recombinant 





evident. Notably, epitopes in the MPER shifted slightly to the N- or C-terminus of the ELDKWA 
sequence, correlating with the rotation of the MPER domain (Fig. 40, Table 12). From all antisera tested, 
sera from mice in group F1-M2 recognised an epitope with complete identity to the 2F5 epitope.  
 
 
Fig. 40. Epitopes recognised by the immune sera of FPPR/MPER protein immunised mice. Microarrays spotted with 15er overlapping 
peptides were probed with serum pools of the indicated mice group at a dilution of 1:100 and bound antibodies were detected by a 
fluorescent secondary antibody. Epitopes were defined as shared amino acids with signal intensity above 4000 relative fluorescence units 
(RLU). Dependent on the administered antigen, shifting or broadening of the antibody response to the 2F5 epitope ELDKWA in MPER is 
observed, whereas FPPR epitopes were basically identical (see also Table 12). 
. 
 
Table 12. Epitopes recognised by group-pooled antisera after 
immunisation with indicated loop antigens. 
   
 
 Epitope. 
Antigen E1 domain  E2 domain 
 
F0-M0 TLTVQARQL         ELLELDKWA 
F0-M1 TLTVQARQL   NEQELLELD 
F0-M2 TLTVQARQL         ELLELDKWA 
 
F1-M0 TLTVQARQL         ELLELD 
F1-M1 TLTVQARQL NEQELLELDKWA 
F1-M2 TLTVQARQL                  ELDKWA 
 
F2-M0 TLTVQARQL         ELLELDKWA 
F2-M1 TLTVQARQL         ELLELDKWA 








3.3.4 Analysis of the neutralising capacity of induced antisera  
To test for potential HIV-1 specific neutralising antibodies in the produced antisera, neutralisation tests 
based on TZM-bl indicator cells were performed (Table 13). Although the individual constructs differed 
by only few amino acids, some of the sera showed titratable neutralising activity at serum dilutions of 
1/10-1/80 from which representative data of the 1/40 dilution are summarised in Table 13. Substantial 
neutralisation was observed only with sera from animals immunised with antigens F1-M1 or F1-M2 and  
 
 
 Table 13. Neutralisation of HIV-1 pNL-4.3 and SIVmac239 by mice antisera at a 1/40 dilution on TZM-bl indicator cells. 
 
Sample Neutralisationa 
 HIV-1 SIVmac239 
Non-infected - - 
Infection - - Sample Neutralisationa 
2F5 (10 µg/ml) 70% -  HIV-1 SIVmac239 
PBS-PI 20% - F1-M1-PI 13% - 
PBS-1 29% - F1-M1-1 57% - 
PBS-2 17% - F1-M1-2 68% - 
PBS-3 - - F1-M1-3 57% - 
PBS-4 - - F1-M1-4 69% - 
F0-M0-PI - - F1-M2-PI 26% - 
F0-M0-1 56% - F1-M2-1 80% - 
F0-M0-2 29% - F1-M2-2 59% 22% 
F0-M0-3 41% - F1-M2-3 43% - 
F0-M0-4 1% - F1-M2-4 56% - 
F0-M0-5 - - F1-M2-5 58% - 
F0-M1-PI - - F2-M0-PI 13% - 
F0-M1-1 34% - F2-M0-1 25% - 
F0-M1-2 25% - F2-M0-2 58% - 
F0-M1-3 28% - F2-M0-3 52% - 
F0-M1-4 26% - F2-M0-4 62% - 
F0-M1-5 - - F2-M0-5 65% - 
F0-M2-PI - - F2-M1-PI 5% - 
F0-M2-1 - - F2-M1-1 50% - 
F0-M2-2 - - F2-M1-2 41% - 
F0-M2-3 37% - F2-M1-3 55% - 
F0-M2-4 29% - F2-M1-4 54% - 
F0-M2-5 25% - F2-M1-5 59% - 
F1-M0-PI 27% - F2-M2-PI 18% - 
F1-M0-1 30% - F2-M2-1 60% - 
F1-M0-2 30% - F2-M2-2 72% - 
F1-M0-3 42% - F2-M2-3 61% - 
F1-M0-4 24% - F2-M2-4 70% 14% 
F1-M0-5 74% 22% F2-M2-5 64% - 








all constructs having two deletions in the MPER flanking regions (F2-X antigens, Table 13). 
Importantly, this neutralising activity clearly exceeded the level of background neutralisation observed 
in some of the pre-immune sera or antisera from the PBS group. Furthermore, weak neutralisation of 
SIVmac239 was found only in three sera, indicating that neutralisation was indeed HIV-1 specific. Due 
to the low amounts of antisera available from mice, serum characterisation was limited to the 
experiments performed above. As the number of immunisations necessary to obtain nAb, the breadth of 
neutralisation as well as further confirmation of MPER-mediated neutralisation e.g. by using affinity 
purified IgGs was also from interest or needed, the immunisation study was repeated in hamsters using 
the antigens that yielded nAb (F1-M1 to F2-M2). Proteins were emulsified in IFA (250 
µg/animal/immunisation), administered through the same route (i.m and s.c) and at a time schedule as 
before (three weeks interval), but boosting was continued for up to five times with the aim to further 
increase nAb levels. For reasons that are not completely clear, the overall immune responses induced in 
hamsters was extremely low (gp41 ELISA reactivity ~0.15 AU at serum dilution of 1:100 compared to 
~0.3 AU at dilutions of 1:1000 in mice), the induced antibodies were only directed against the FPPR 
and no neutralisation was observed (data not shown). This suggested that the applied immunisation 
procedure might has to be altered to obtain robust immune responses in hamsters or that species-specific 
differences exist that prevent the formation of MPER-directed antibodies here. Repetition of the study 
should therefore be performed, preferably in rats, guinea pigs or rabbits, from which larger amounts of 
serum can be obtained. 
 
3.4. Construction of replicating FFV/HIV-1 hybrid vectors 
The previous results demonstrated that the Bet/HIV hybrid strategy can be successfully applied to induce 
HIV-specific antibodies with advantageous characteristics. In combination with the improved loop 
antigens obtained through systematic optimisation, this approach thus seemed most promising for a 
transfer into replicating FFV. The following section describes the construction of such hybrid vectors 






3.4.1 Construction of chimeric FFVs containing HIV-1 epitopes 
Chimeric viruses were constructed by two sequential cloning steps (Fig. 41). First, a unique NheI 
restriction site together with a His-tag was fused to the C-terminus of Bet in the FFV molecular clone, 
giving rise to the plasmid pCF7-Bet-His. In this construct, HIV-1 sequences were afterwards introduced  
 
Fig. 41. Construction of FFV vaccine vectors. (A) Nucleotides encoding Asp and Ser residues corresponding to a NheI restriction site and a C-
terminal His-tag were introduced directly before the Bet stop codon by assembly PCR using primers I and II for PCR 1 and primers III and IV 
for PCR 2, both having the nucleotide sequence of the His-tag in common. After amplification of the full-length PCR amplicon with primers I 
and IV and PCR1 and PCR2 DNA as template, digestion with AgeI (compatible with Kpn2I overhangs) and SphI allowed introduction into the 
Kpn2I/SphI- digested molecular clone pCF-7 yielding the plasmid Bet-His. (B) Plasmids Bet-F2-M0, F2-M1 and F2-M2 were cloned by 
amplification of HIV-1 sequences from the prokaryotic expression plasmids pQE-F2-M0, F2-M1 and F2-M2 described in the text. In PCR1 
primers V containing a NheI restriction site and VI encoding nucleotides of the U3 region were used. PCR 2 took the wild type pCF-7 plasmid 
as template and included parts of the MPER in the 5’ primer overhang and amplified the U3 region beginning after the Bet stop-codon down 
to the SphI restriction site with primers VII and primer IV. The full-length amplicon was obtained after an additional PCR using outer primers 
V and IV. Plasmid Bet-E2 was prepared with primers VIII encoding a NheI restriction site and primer VI with plasmid pQE-F2-M0 as template 
for PCR 1. PCR 2 was identical to cloning of Bet-F2-X constructs described above. The full-length amplicon was constructed after an additional 
PCR using outer primers VIII and IV. Full-length inserts were digested with NheI and SphI and cloned into the identically treated Bet-His 
construct. All plasmids were sequenced in the cloned regions to confirm insert integrity. Green arrows: forward primer; red arrows: reverse 




by using the new NheI site and the unique SphI site located in the U3 region of the 3’ LTR. The required 
inserts were generated by fusion PCR, joining together the HIV-1 sequences amplified from the loop 
expression plasmids and the FFV LTR region starting behind Bet and ending with the SphI site. As HIV-
1 antigens, the E2 domain and the FPPR/MPER loop antigens F2-M0, F2-M1 and F2-M2 were selected 
for transfer into FFV. This was based on the previous finding, that including the MPER alone resulted 
in highest antibody titres with ELDKWA specificity when compared to the initial Bet-E1-E2 antigen. 
The loop antigens chosen comprised the proteins which contained two deletions in the FPPR flanking 
region (F2-X) since they were recognised best by 2F5 and resulted, at least in mice, in the induction of 
neutralising antibodies. As in the recombinant Bet/HIV-1 antigens, spacer amino acids between Bet and 
the fusion parts were included to assure that HIV-1 epitopes protrude from the Bet carrier and are readily 
accessible. Figure 42 gives an schematical overview of all constructed FFV clones. 
 
 
Fig. 42. Construction of chimeric FFV. Schematic illustration of the FFV molecular clone pCF-7 and amino acids introduced in frame to the C-
terminus of Bet. The flanking 3’ LTR sequences were left unaltered. Between Bet and inserts, spacer amino acids (AS for Bet-His, ASGAGAGGG 
for the other constructs) were cloned. Labelling of the HIV-1 MPER (E2) or FPPR and MPER domains is corresponding to that in Figure 37. 




3.4.2 Characterisation of chimeric viruses 
To test if epitope insertion was compatible with virus production, the constructed plasmids were 
transfected into 293T cells and supernatants analysed for the presence of infectious particles by titration 
on FeFAB indicator cells. All vectors gave rise to functional progeny virus, with titres that were 
comparable to the only slightly modified Bet-His construct and reached ~104 IU/ml (Fig. 43A). 




expression of the Bet or Bet/HIV-1 fusion proteins at the expected sizes. Furthermore, all constructs 
modified to contain the MPER epitope also specifically reacted with the 2F5 antibody, confirming that 
HIV-1 epitope expression is achieved (Fig. 43B). Notably, the enhanced recognition by 2F5 observed 
for antigens F2-M0 to F2-M2 was compensated by a reduced expression level of these somewhat larger 
fusion proteins compared to Bet-His and Bet-E2, respectively (Fig. 43B). As the vectors were intended 
for long-term antigen delivery the stability of replication and transgene expression was an important 
point to investigate. To address this, supernatants from the individual constructs were passaged every 
three to four days on permissive feline CRFK cells and virus titres and transgene expression monitored  
 
 
Fig. 43. Characterisation of chimeric FFV. (A) Titration of supernatants from transfected 293T cells on FeFAB indicator cells. Progeny viruses 
with titres comparable to that of pCF-7 containing only a His-tag were obtained. (B) Transgene expression in transfected 293T and directly 
transduced CRFK cells using supernatants from transfected 293T cells. Cell lysates were prepared two days post transfection or three days 
after transduction, separated by SDS-PAGE, immunoblotted and then probed with 2F5 or a Bet specific antiserum. Transgene expression was 
specifically detected with 2F5 in all chimeric constructs containing the MPER but not Bet-His or a GFP expressing vector (mock control), 
confirming the integrity of constructed clones. (C) Infectivity of chimeric viruses and or a GFP expressing vector (mock control) on feline cells. 
Cleared supernatants from transfected 293T were transferred to FeFAB indicator cells which were stained 3 days later with X-gal solution to 







Fig. 44. Viral titres and transgene expression after extended passaging on feline CRFK cells. (A) Titres of chimeric viruses and or a GFP 
expressing vector (mock control) titrated on FeFAB indicator cells after the number of indicated passages. (B) Transgene expression after 





with time (Fig. 44). The viral titre of the Bet-His hybrid steadily increased upon passaging on these cells 
with final titres approaching 1x106 IU/ml. In case of the constructs that contained the MPER or 
FPPR/MPER inserts, an initial decrease of virus titres was observed. However, starting with passage 
three and five, FFVs expressing Bet-E2 and Bet-F2-M1 or Bet-F2-M2, respectively, finally also 
recovered to levels indistinguishable from the Bet-His construct with 1x106 IU/ml in passage ten (Fig. 
44A). In contrast, the vector expressing the Bet-F2-M0 antigen maintained low level replication (~5x102 
IU/ml) throughout the whole experiment. As this pattern suggested that adoptive arrangements within 
FFV may occurred to compensate the burden of insert expression, it was essential to examine if 
transgene expression is maintained also in the final passages. Using cell lysates from passage ten for 
immunoblotting with 2F5, the presence of the 2F5 epitope could be confirmed for the Bet-E2 as well as 
the Bet-F2-M1 and Bet-F2-M2 chimeras (Fig 44B). In contrast, the Bet-F2-M0 hybrid did not show any 
reactivity with 2F5, indicating that it had either lost its transgene or transgene expression could not be 
detected due to the low levels of replication/number of infected cells. Analysis of cell lysates from 
passage 1-10 with a Bet-specific antiserum confirmed that the latter was the case and Bet expression 
vanished after the third round of transfer to fresh cells (data not shown). In summary, this results 
demonstrated that the constructed FFV hybrid vectors efficiently present the intended HIV-1 epitopes 






The obstacles in developing a HIV vaccine are manifold. They lie in the nature of HIV infection from 
which no spontaneous cure in patients has been observed, the high diversity of the virus as well as its 
rapid development of mutations which hamper universal vaccine development (9). Moreover, quick 
establishment of HIV reservoirs and viral latency, active immunosuppression and destruction of the 
biological system responsible for antiviral immunity further complicates the issue (43). The best way to 
avoid the drawbacks associated with HIV infection and subsequent immune dysfunction would be a 
vaccine capable to completely block HIV entry and its integration into target cells where it may persist. 
Here, bnAb represent a promising target to achieve this goal, as such antibodies effectively clear the 
virus and can provide sterilising immunity (66, 234, 235). Furthermore, they are able to eliminate 
potential breakthrough infections by mediating killing of infected cells through mechanisms of ADCC 
or ADCVI and they can block HIV transcytosis at the virological synapse (30, 49-52). Whereas 
induction of bnAb by immunisation remains a challenge, factors correlating with their emergence during 
natural HIV infection have been identified and comprise high viral loads during the acute phase, low 
CD4 T cell counts and the time the individual is infected (35, 36, 236, 237). This suggests a role for 
high level of Env available during early stages and extended antigenic stimulation to this antigen as a 
requirement for induction of bnAb and is further supported by the high degree of somatic mutation that 
can be found in the genes of most of these bnAb (53, 67, 238, 239). Considering this, recent attempts 
aim to design B cell lineage immunogens to stepwise recapitulate antigenic stimulation over time and 
to overcome potential depletion of self-reactive bnAb antibodies by immune tolerance mechanisms (67, 
77, 240). However, it has to be noted that only 20-30% of HIV positive individuals develop such 
antibodies even over time (32, 34), that HIV triggered B cell dysfunction might be responsible for the 
slowed down antibody responses (241-243) and that some studies report the successful induction of 
bnAb by rather simple immunisation regimens (244-247). Overall, this indicates that in healthy 
individuals a suitable immunogen presented as B cell prime, to which antibody responses can further 
improve through affinity maturation might present a way for the effective induction of bnAb in vaccine 




suitable in this regard, since affinity maturation to an immunogenic epitope is driven by such a delivery 
system per se. Furthermore, this approach does not require a comprehensive knowledge of antibody 
maturation pathways, which are complex and difficult to determine (77). The first live attenuated 
vaccine viruses based on SIVΔnef belong to the most potent inhibitors of a subsequent infection. 
Unfortunately, their capacity to revert to a more virulent phenotype and issues related to vector 
integration have excluded their use in humans (248). Nevertheless, the fact that live vectors have an 
unmatched ability to induce durable and multicomponent immunity against various pathogens has 
preserved the interest in such vectors high (249, 250). Recently, several reports on the successful 
application of replicating viruses for preventing disease have reinforced the search and development of 
safe and efficient vectors as HIV vaccine platforms (120-123, 125, 137, 141, 251, 252). Due to their 
intrinsic properties, FV meet most of the criteria such a vector should have, including a good safety 
profile, high immunogenicity, genetic stability as well as a low prevalence in humans. The fact that they 
replicate in mucosal and lymphoid tissues represents another advantage for their use as HIV vaccine 
vectors. Despite these obvious benefits, the current study represented the first one aiming to develop FV 
for the induction of HIV bnAbs and two strategies, based on the FV TM protein and Bet were tested. 
Although the TM protein based approach did not result in replicating vectors, the data obtained for the 
FV expressing Bet/HIV fusion proteins are promising and encourage further exploration of this strategy 
for the purpose of HIV vaccine delivery. In the following sections, the individual parts of the project 
eventually leading to these replicating vectors will be shortly discussed. 
 
4.1 Characterisation of the humoral immune response to the FFV TM protein 
Although Env-specific antibodies can be frequently detected in FV positive antisera, any detailed studies 
on their epitope specificity were absent in the beginning of this project or based on the SU subunit only 
(217). That TM protein-directed responses have not been investigated for FV might be explained by the 
difficulties usually associated with the production of sufficient amounts of them (253, 254). In this study 
milligram amounts of recombinant PFV and FFV TM proteins with defined structure in were produced 
with the help of a newly developed assay for optimisation of protein expression (220). Thereby, 




compared to standard expression conditions. Similar significant differences were observed when 
parameters were optimised for other project-related (FFV Bet, E1-E2 loop antigens) and non-related 
(PERV gp70, KoRV p52) proteins, demonstrating the importance of matching vector, host and growth 
conditions to achieve high production rates. The initially described set-up was designed to select for 
highest overall expression since both TM proteins were highly insoluble. However, including a 
centrifugation step after lysis also allowed screening for best conditions for soluble proteins and was 
used to identify ideal parameters for soluble expression of FFV Bet (Fig. 29). This point is an important 
improvement, because soluble expression warrants biological activity and integrity of proteins including 
any conformational epitopes. It also avoids establishing a refolding strategy which is usually 
cumbersome and time-consuming (255-257). The assay was useful for TM proteins known to be hard 
to express but also easily adoptable to proteins of other origin. Since screening conditions were highly 
reproducible in large-scale, this assay represents an efficient tool to rapidly overcome expression 
problems for new protein targets and largely reduces efforts and costs of subsequent downstream-
processing steps. 
 
The availability of both TM antigens was a prerequisite to study TM-directed immune responses during 
FV infection and after immunisation. By analysing about 400 cat sera in a newly established ELISA, it 
was demonstrated that the FFV TM protein is an important antibody target during natural FFV infection 
and that TM responses correlated well with FFV Gag and Bet seroreactivity (160). It therefore 
represented a reliable antigen for serological screening and was used to determine for the first time the 
prevalence of FFV infection here in Germany, which was found to be 39% (221). This prevalence is 
consistent with results obtained in other European areas (201, 258-260) but has been found to vary from 
4-70% in other geographical regions (261-264). The significant increase of FFV infection observed after 
one year of birth might be explained with attainment of sexual maturity, where cats start roaming and 
get in contact to other cats increasing the probability of infection. The positive correlation found for the 
castration status and FFV infection could be due to similar reasons, because straying of castrated rather 
than non-desexed animals is tolerated by pet-holders. Alternatively, castration itself might influence the 




it would be interesting to analyse seroreactivity also against the PFV TM protein in primate and non-
human primate serum samples where current testing also relies mainly on Gag and Bet (161, 265, 266). 
However, as access to substantial amounts of such sera was not given during the time of this thesis, this 
issue will be subject of future experiments.  
 
Having identified several  cat sera with varying degrees of FFV TM reactivity (serum titres ranging from 
1:100-1:20.000), mapping of the epitopes recognised by these specimens was an essential information 
for the subsequent FFV/HIV-1 epitope exchange. Here, an important result was obtained when sera from 
naturally infected cats and TM protein-immunised animals were compared. Whereas immunised 
animals developed antibodies against the FPPR and the central region of FFV TM, naturally FFV 
infected cat sera contained antibodies exclusively directed to the FPPR and MPER regions but reactivity 
to the central, glycosylated domain was absent (Fig. 20). This suggested that the immune response to 
FFV TM is directly influenced by the properties of the antigen presented to the immune system. In case 
of the recombinant TM proteins obtained from E. coli, differences compared to the authentic FFV Env 
protein from eukaryotic cells comprised the lack of glycosylation, trimerisation, disulphide-linkages, 
absence of the SU subunit that might sterically protect some epitopes from being accessible (116) as 
well as the lack of presentation of the TM protein in a lipid context. Notably, such strong deviations in 
immune responses were also observed for bacterially-expressed gp41 of HIV-1, but not for the TM 
proteins of FeLV, KoRV and PERV, which are smaller in size and less or non-glycosylated. This 
highlights the importance of such comparative structural, functional and immunological studies to assess 
common and unique requirements for production and purification of antigens from various viruses. As 
a logical consequence of the differences observed between both expression systems, subsequent 
experiments relied on eukaryotic expression vectors encoding the full-length FFV Env protein.  
 
Next to their epitope specificity, it was from interest to examine if neutralising activity of the antisera 
correlated with TM reactivity. Two high-throughput FFV neutralisation assays, based on a novel qRT- 
PCR measuring FFV provirus integration (Fig. 12) and a modified indicator cell assay scaled down to 




of TM protein binding and FFV-FUV-7 neutralising antibodies, no obvious relationship between both 
parameters was apparent. This is consistent with results from other groups showing that serotype-
specific neutralisation of FFV-FUV or F17/951 isolates is primarily mediated by antibodies to the central 
and C-terminal domains of the SU protein (217, 267). It would be interesting to examine if neutralisation 
can be detected when antibodies affinity-purified using the TM proteins are used in these assays, as this 
might provide extended possibilities for an epitope exchange as performed here.  
 
4.2 The FFV TM protein as HIV-1 epitope scaffold 
Compared to classical HIV-1 Env antigens, scaffolding HIV epitopes into immunogenic regions of 
foreign proteins represents an elegant way to induce antibodies to desired epitopes and allows 
modification of its structure dependent on the backbone selected (5, 268). In parallel, this strategy 
prevents responses to unwanted, but otherwise highly immunogenic regions of Env, since only a small 
part of the full length protein is usually included (5, 87, 89, 269-271). This issue is relevant for the HIV-
MPER epitope selected here, since non-neutralising antibodies binding adjacent to the actual MPER 
epitope may mask critical residues for nAb engagement and thus inhibit virus neutralisation or hide the 
epitope from being accessible for B cells (272, 273). Introducing HIV epitopes into FV TM proteins 
was chosen as a strategy as it should principally allow epitope display on the virus surface at a FV typical 
high density, in a trimeric form and a lipid environment such as in the native HIV-1 context. Next to 
this, earlier findings showed that MPER-directed antibodies contribute to virus neutralisation during 
various retroviral infections, suggesting that similar regions might also exist for FV (182, 185-187, 274-
276). Despite a direct linkage to virus neutralisation, the experiments clearly showed that the FPPR and 
MPER domains were immunogenic during FFV infection and rationalised the use of the FFV TM 
protein as epitope scaffold. After defining immunogenic FPPR and MPER core regions from the epitope 
mapping data, the final insertion positions for HIV-1 epitopes were selected by combining the 
immunological data with bioinformatic analysis for secondary structure, amino acid hydrophobicity, 
surface exposure and spacing to neighbouring functional domains. Whereas this approach did not result 
in functionally processed FPPR hybrids, HIV MPER insertion into FFV Env was compatible with Env 




to promote infection of new cells, excluding their further use for the development of replicating vectors. 
It might be possible to design chimeric constructs that remain fusion-competent by shortening the 
introduced HIV-1 sequences, by testing additional insertion positions or by mutation of selected FFV 
residues to artificially construct a 2F5 or 4E10 epitope. This task is yet quite challenging, as essential 
FV MPER residues critical for Env function and virus infectivity have not been identified as in case of 
HIV-1 (78, 277). Since they were released as SVPs, therewith placing the HIV-1 MPER in a lipid 
environment shown to influence MPER epitope accessibility and structure (188, 278-280), testing 
immunogenicity of such SVPs was considered worth exploring. The fact that only weak antibody 
responses to the TM protein and the HIV MPER domain were induced after DNA prime and the SVP 
boost was most likely a result of the small amounts of SVPs used here (100, 45  and 110 ng of EnvG2, 
MPER1 or MPER SVPs per rat compared to 250 µg of antigen when recombinant proteins were used), 
which were probably too low to mount substantial B-cell responses. Furthermore, no adjuvant was used 
in these experiments to avoid a loss of SVP-integrity during antigen/adjuvant mixing or dissociation of 
particles through lipid adjuvant components. Enhanced responses might be triggered by including 
genetic adjuvants during the DNA prime and the use of substantial amounts of SVPs (e.g. 100 µg per 
animal). However, the production of such large amounts by transient transfection is technically 
challenging and would have required fermentation of cells, what simply exceeded the capacity of both 
labs. In the meantime, wildtype and MPER-containing FFV Env sequences have been subcloned into 
retroviral vectors and SVP expressing stable cell lines were established. Systematic selection of the 
expression cell lines, growth conditions and media has increased yields several-fold and now allows 
continuous harvesting from cells, providing access to much higher amounts of antigen. An immunisation 
study with these SVPs is currently ongoing and will help to evaluate their potential as HIV vaccine 









4.3 FFV Bet/HIV-1 fusion proteins induce high titred HIV-1 specific antibodies in vivo 
In a second approach, HIV-1 epitopes were appended to the FFV Bet accessory protein and recombinant 
proteins were produced to allow characterisation of such antigens. It was essential that the final products 
were soluble in physiologic buffers, since a conformational epitope in the Bet-E1-E2 protein would be 
formed under such conditions only. Despite all efforts, insufficient yields of soluble protein were 
obtained even after systematic optimisation (Fig. 29). After purification under denaturing conditions, 
successful renaturation was observed in presence of L-Arginine, which is an established additive that 
prevents aggregation of insoluble folding intermediates and therefore increases refolding efficiency 
(281, 282). Interestingly, interaction of renatured Bet with its natural ligand APOBEC (207, 283, 284) 
was dependent on disulphide bonds in the refolded Bet protein, since only in presence of a redox-system 
significant binding was observed (Fig. 30). Together with the fact that no distinct APOBEC interaction 
domain could be identified by using Bet deletion mutants (283), this indicates that a discontinuous 
surface area stabilised by disulphide bridges might be responsible for creation of the contact interface. 
Structural characterisation of the Bet protein produced in this study in complex with feline APOBEC 
would be an interesting project giving insights into the mechanisms FVs have evolved to counteract 
cellular immunity and which are quite distinct from that described for HIV-1 Vif (207). When the 
protocols established for Bet were used for Bet/HIV-1 fusion proteins, they were soluble in phosphate 
buffers and had a defined structure. However, protein solubility was concentration-dependent and 
solutions exceeding 1 mg/ml had a high tendency to aggregate, preventing determination of affinity 
constants for some antigens in SPR experiments (Table 11). This observation can either be explained by 
the presence of trace amounts of misfolded protein in the sample, triggering aggregation of folded 
proteins or, more likely, by the odd number of 13 cysteines present within FFV Bet. Even in case that 
most cysteines are involved in protein stabilisation and thus oxidised, a single cysteine residue remains 
unpaired in an active, reduced state favouring intermolecular interactions or induction of disulphide 
scrambling, particularly at high protein concentrations where molecule interactions are increased. 
Supporting this idea, 1-3 free cysteine in preparations of oxidised Bet could be frequently measured 
using Ellman’s reagent (data not shown). Including low amounts of reducing reagent might prevent 




disulphides and thus Bet structure remained hard to predict. Besides these technical issues, the affinity 
for mAb 2F5 to the generated fusion proteins was excellent, with comparable or even better binding to 
the MPER domain when compared to constrained peptides or other MPER epitope scaffolds (5, 88, 89, 
271). Moreover, although overall affinity of 4E10 to the antigens was weak, including FPPR residues 
in one antigen had a beneficial effect on 4E10 binding, demonstrating that this domain indeed positively 
influences MPER epitope accessibility. The improved binding could result from an increased alpha 
helical content in C-terminal ELDKWA residues, which has been observed in presence of hydrophobic 
FPPR residues (95) and found to enhance affinity for 4E10 (86, 90, 91). Independent of the antigen 
selected, fusing epitopes to the C-terminus of Bet together with some spacer residues was overall an 
efficient mean to present them in an antibody-accessible form and high levels of antigen-binding and 
HIV-1 epitope-specific antibodies were induced when these proteins were injected into rats. For all 
antigens that included the HIV MPER domain, the elicited antibodies predominantly targeted the 2F5 
epitope and those were able to bind to native Env presented on infected cells. The dominance of 
ELDKWA directed responses, whereas 4E10 epitope-binding antibodies were virtually absent, might 
be an result of better presentation of the 2F5 epitope in the Bet/HIV proteins, since high affinity binding 
to an epitope is the driving force triggering proliferation and differentiation of B cells to plasma cells 
(285, 286). It is noteworthy, that in presence of FPPR residues the immune response to that domain 
frequently exceeded that to the MPER by 1-2 logs. This could present an issue for the use of FPPR-
constrained MPER antigens, because high immunogenicity of the FPPR might bias the strength of 
MPER responses although this domain is actually included for stabilisation only. It would be advisable 
to introduce modifications of the FPPR that immunologically silences FPPR responses by maintaining 
its confining properties as has been demonstrated for some therapeutic proteins (287, 288). As in 
previous studies, the antibodies induced by the Bet/HIV-1 fusion proteins were not able to inhibit HIV-
1 infection in TZM-bl cell-based neutralisation assays, despite their high abundance, recognition of the 
2F5 epitope and binding to native Env. This suggests that either the antigens did not provide the 
structural features required for their induction, what is supported by the results obtained later with 




It has to be noted, that in later experiments some of the antisera from rat groups injected with MPER-
containing antigens showed indirect antiviral activity in ADCC assays using MPER peptide-loaded 
CEM cells and human PBMCS (Steve Norley, RKI, data not shown). Considering that enhanced lysis 
(10-30%) compared to non-pulsed cells or pre-immune controls was observed in this system is 
remarkable, since binding of human NK effector cells to rat IgGs is mainly limited to the IgG2a 
subclasses (289), whereas IgG1 and IgG3 are usually found to have highest ADCC activity (30, 290, 
291). The actual capacity of the sera to induce ADCC is thus probably higher, but to fully explore 
antiviral functions of these sera, a system based on rat effector and target cells would be desirable which 
is not available to our knowledge. In general, mechanisms such as ADCC and ADCVI play an important 
role for protection from HIV infection and particularly MPER directed antibodies have been found to 
be involved in blocking viral transcytosis in intestinal epithelial cells or prevent cell-to-cell transmission 
through the viral synapse (49, 51, 292). They were are also considered responsible for the moderate 
protection observed in the recent RV144 trial (293-295). Exploring such alternative antibody functions 
is principally indispensable to draw complete pictures of the antibody response induced by novel 
antigens. Still, as assays are usually established for human and simian antibodies, addressing these 
questions is challenging for experiments in rodents as performed here. In summary, the described 
experiments showed that Bet fusion proteins can be successfully employed to induce epitope-specific 
antibody responses in vivo, what prompted further examination of this strategy. 
 
4.4 Improved FPPR/MPER antigens induce HIV-1 neutralising antibodies in mice 
Whereas the foregoing results rationalised the use of Bet as carrier protein, the performance of the loop 
stabilised FPPR/MPER antigen used in these experiments was rather moderate. Although higher affinity 
for 4E10 was achieved by including FPPR residues, 4E10 epitope specific-antibodies were not induced 
during immunisation (Fig. 35). Furthermore, in case of 2F5, the loop antigen showed reduced affinity 
to its epitope compared to the Bet-E2 antigen which encoded the MPER domain alone (Fig 33, Table 
11). This supported the view that linker length or the spacing of FPPR and MPER residues in this initial 
construct was suboptimal for the formation of a 2F5 conformational epitope. Importantly, this situation  




constrained by a linker and therefore can spontaneously assemble into an energetically favoured 
complex (92, 96, 189). In order to make use of the 2F5 epitope-dominated response observed after 
injection into rats, it was sought to modify antigens to achieve a FPPR/MPER positioning in which 
binding for 2F5, rather than 4E10 is enhanced. A set of antigens was cloned in which the FPPR/MPER 
flanking residues were systematically shortened through single amino acid deletions. In line with the 
theory that such mutations should alter surface exposure of distinct residues in the predominantly helical 
domains (81, 296), significant differences in bnAb binding characteristics as well as the propensity of  
the antigens to form trimers were observed (Fig. 38). The latter finding is consistent with previous results 
showing that trimer formation is influenced by FPPR residues (93) and extends these data as it suggests 
that the influence is not only residue but also position dependent. Furthermore, such stepwise truncations 
also resulted in changes of the strength and quality of MPER-directed immune responses in mice, 
including the induction of higher titres of binding antibodies and a shift of the epitope recognition pattern 
in dependence to the antigen administered (Fig. 40, Table 12). Most importantly, only a subset of these 
antigens was capable to prevent HIV-1, but not SIVmac239 infection  in TZM-bl cells when compared 
to pre-immune control sera. These data strongly suggested that the MPER structure required for 
induction of nAb is formed only in a distinct positioning of FPPR and MPER residues and it would be 
worthwhile to decipher the structural differences of these antigens to those that induced binding 
antibodies only. Notably, these results are consistent with a recent publication by Dawood et al., which 
reports the induction of bnAbs in mice by use of a cell line expressing a linked NHR/CHR antigen as 
immunogen (245). For reasons that are not completely clear, the results obtained in mice could not be 
reproduced when the study was repeated in hamster and in contrast to the immunisations performed in 
BALB/c mice, the overall immune response observed was weak and neither MPER-directed nor nAb 
were induced (data not shown). This might be linked to the differences in the genetic background of 
both species resulting in varied B cell receptor reservoirs or ability to process and present certain 
peptides on MHC class II receptors. In line with this, distinct HLA alleles associated with HIV/SIV 
protection or delayed disease progression have been identified in man and primates (297-300). Deviation 
of experimental results dependent on the animal system and the resultant limitations for predicting 




conclusions on the ability of the loop antigens to induce protective responses, the study should be 
performed in humanised mice followed by subsequent HIV-1 challenge, which represents one of the 
most stringent models to evaluate novel vaccine candidates.  
 
4.5 Chimeric FFV vectors expressing Bet/HIV-1 fusion proteins 
Based on the results obtained above, three of the five loop antigens as well as the MPER domain alone 
were chosen for subcloning into the FFV molecular clone. This selection was basically driven by the 
observations that these antigens showed highest affinity to 2F5, induced significant levels of 
ELDKWAS specific antibodies after immunisation and showed the ability to induce nAb in mice. As 
before, the HIV-1 inserts were fused to Bet with identical spacing/linker residues to assure an antigen 
structure most closely resembling that of the previously characterised recombinant antigens. Moreover, 
separating the HIV epitopes from Bet was considered important since they might sterically interfere 
with the function of Bet, which would be essential to allow effective replication in APOBEC-positive 
cells (207, 283, 284). In a previous study, this was achieved by including the FFV protease cleavage site 
between Bet and the transgene (118, 209). However, as secretion of the intact Bet/HIV-1 fusion proteins 
from infected cells was desirable to maintain epitope conformation and to stimulate surveying immune 
cells, this was not included here. It is important to note that fusion to Bet in that case most probably 
prevents the trimerisation of the FPPR/MPER antigens observed when the proteins were analysed alone. 
It is not clear how this affects their immunogenicity, but internal promoter driven, Bet independent 
expression of FPPR/MPER antigens with a secretion signal might be considered as an alternative way 
of delivery of these antigens. The applied cloning strategy fused the HIV-1 inserts to Bet by leaving the 
subsequent 3’ LTR unaltered instead of truncating the corresponding sequences (Fig. 41, Fig. 42). 
Although such vectors have been found to be genetically less stable compared to those with a truncated 
3’ LTR, chimeric vectors with an intact LTR were superior in inducing antibodies to the desired epitope 
(118). Furthermore, the instability observed in these studies was inversely correlated to the insert size. 
The single MPER domain and the longest FPPR/MPER inserts introduced here were of small or 
intermediate size (28 and 70 residues) compared to the previous 39, 105 and 150 residues of feline 




similar fashion (118). Consistent with these thoughts, the resulting chimeric vectors gave raise to 
infectious virus similar to the wildtype virus, expressed the Bet/HIV-1 fusion proteins at the expected 
sizes and were able to replicate in APOBEC-expressing feline CRFK cells (Fig. 43, Fig.44). Dependent 
on the cloned insert, virus replication was somewhat compromised in the initial passages, suggesting 
that adoptive mutations were probably necessary to compensate for expression of the highly 
hydrophobic HIV epitopes (Fig. 44). In case of the FFV Bet-F2-M0 vector, this resulted in low level 
replication vanishing after the third passage (data not shown). It is possible that the HIV-1 fusion part 
in this construct might be misfolded, impairing the ability of Bet to act as APOBEC decoy protein as 
mentioned above. However, in the remaining constructs integrity of HIV-1 epitopes was obviously not 
affected as no change in insert size or recognition by 2F5 was evident. This analysis was further extended 
by sequencing proviral DNA from infected cells of the last CRFK passage (data not shown). There were 
no or up to four independent mutations within Bet for the Bet-His and the Bet-E2 vector, respectively, 
but MPER epitope integrity was not affected. The other two Bet-F2-MX vectors were sequenced after 
cloning. Seven (Bet-F2-M1) and nine (Bet-F2-M2) of 11 clones analysed encoded the entire HIV MPER 
epitope, whereas the remaining clones expressed truncated forms of Bet due to premature stop codons 
or insert deletion and fusion to LTR sequences (data not shown). Therefore, some degree of genetic 
rearrangements does occur in these vectors and it will be important to analyse their behaviour in an in 
vivo situation. Alternatively, a set of additional vectors incorporating the suggestions mentioned above 
might be constructed and again analysed in vitro before proceeding to the animal model. Overall, the 







The induction of neutralising antibodies by immunisation represents one of the best strategies to prevent 
subsequent virus infections. However, whereas such antibodies form the basis of several vaccines 
available today, attempts to induce protective immune responses against the human immunodeficiency 
virus (HIV) failed till now. This work aimed to establish and evaluate a novel vaccine approach based 
on apathogenic, persistently infecting foamy virus (FV) to exploit their continuous antigen delivery and 
immune stimulation. To allow testing of such novel vectors in vivo, the feline FV (FFV) was used as 
model for later application in in cats. In a first approach, the transmembrane envelope (TM) protein of 
FFV was investigated as potential epitope scaffold. With the help of recombinantly produced antigen it 
was demonstrated that the TM protein is a strong immunogen during natural FFV infection and used to 
serologically determine for the first time the FFV prevalence in Germany. After immunogenic regions 
within FFV TM were mapped, replacing these domains through the membrane proximal external region 
(MPER) of the HIV TM protein, an epitope recognised by several HIV-1 broadly neutralising antibodies 
(bnAb), was accomplished. The generated chimeric FFV/HIV-1 Env were released from transfected 
cells as subviral particles (SVPs), presenting the HIV MPER epitope in a FV typical high density on the 
particle surface, in a trimeric context and a lipid environment and were thus tested in subsequent 
immunisation experiments. However, since they gave rise to fusion-defective FFV, they were 
impractical for application in a replicating system. In a second strategy, fusion proteins of the accessory 
FFV Bet protein and HIV-1 epitopes were therefore evaluated. Characterisation of these antigens 
showed that they were efficiently recognised by the preferred HIV-1 bnAb and elicited binding 
antibodies with identical epitope specificity in immunisation studies. Using further improved HIV-1 
inserts this approach could be successfully transferred into the FFV and resulted in the production of 
infectious, chimeric FFV viruses. Importantly, HIV-1 epitope expression remained stable after extended 
passaging on feline cells, suggesting that these vectors are suitable for studying the effects of affinity 
maturation on the emergence of bnAb responses. Taken together, in this work two new HIV-1 vaccine 
platforms based on SVPs and replicating FFV were developed, which are characterised by a high safety 
profile. In particular the replicating FFV/HIV-1 chimeric viruses thereby represent attractive vectors for 





Die Induktion neutralisierender Antikörper durch Vakzinierung ist eine der attraktivsten Strategien, um eine 
nachfolgende Infektion durch Viren zu verhindern. Während jedoch solche Antikörper die Basis für viele 
bestehende Impfstoffe darstellen, blieben Versuche, vergleichbare Ansätze für das Humane Immundefizienz-
Virus (HIV) umzusetzen, bisher erfolglos. Diese Arbeit diente der Etablierung und Evaluierung eines neuen 
Impfkonzepts basierend auf foamyviralen (FV) Trägerviren, welches sich die apathogene, aber persistierende 
Infektion und dadurch verlängerte Antigenexpression der FV zu Nutzen machen sollte. Im Fokus stand dabei 
insbesondere das feline FV (FFV), um generierte Viren später im Tiermodell testen zu können. Zunächst 
wurde dafür das transmembrane (TM) Hüllprotein des FFV als potentielles Trägerprotein näher untersucht. 
Mittels rekombinant hergestelltem TM Protein wurde gezeigt, dass dieses ein starkes Immunogen während 
der natürlichen FFV Infektion darstellt und erstmals zur Bestimmung der FFV Prävalenz in Deutschland 
eingesetzt. Für den HIV-Impfstoff wurde nach Kartierung immunogener Bereiche im FFV TM Protein ein 
Austausch dieser Domänen gegen die membran-proximale externe Region (MPER) des TM Proteins von 
HIV als Epitop mehrerer breitneutralisierender Antikörper (bnAk) durchgeführt. Die generierten FFV/HIV 
Env Hybride wurden als subvirale Partikel (SVPs) freigesetzt, was Immunisierungsversuche mit diesen 
Antigenen, die die HIV MPER an der Partikeloberfläche in einer FV-typischer Dichte, in einem 
trimerisiertem Zustand und einer Lipidumgebung präsentieren, ermöglichte. Mit diesen FFV/HIV Envs 
pseudotypisierte Viren blieben jedoch replikations-defizient. Als zweite Strategie wurden daher 
Fusionsproteine bestehend aus dem akzessorischem Bet Protein des FFV und den HIV-1 TM Epitopen 
hergestellt. Die Charakterisierung dieser Antigene zeigte eine hochaffine Bindung von bnAk gegen HIV-1 
an diese Antigene sowie die Induktion bindender Antikörper mit identischer Erkennungssequenz in 
Immunisierungsstudien. Die Strategie wurde mit weiter optimierten Antigenen erfolgreich auf das FFV 
übertragen. Die Expression der HIV-1 Epitope blieb dabei auch nach mehrmaligen Passagieren der chimären 
Viren in felinen Zellen stabil und ist daher für Untersuchungen zur Notwendigkeit der Affinitätsreifung für 
die Entstehung bnAk besonders geeignet. Zusammengefasst wurden in dieser Arbeit zwei neuartige HIV-
Impfstoffsysteme basierend auf hybriden SVPs und replizierenden FFV entwickelt, die sich durch ihre hohe 
biologische Sicherheit auszeichnen. Insbesondere die replizierenden FFV/HIV-1 Hybride stellen dabei 
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